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DO YOU WANT TO BET YOUR CHILDREN'S HEALTH ON
POST-MARKET HARM PRINCIPLES? AN ARGUMENT
FOR A TRESPASS OR PERMISSION MODEL
FOR REGULATING TOXICANTS'
By CARL F. CRANOR 2
I. INTRODUCTION
Scientific discoveries can lead to paradigm shifts, not only
within science, but also in society at large.3 In turn, this can modify
how citizens respond to the world around them. Recent develop-
ments in monitoring toxicants in United States citizens and devel-
opmental toxicology provide the background for rethinking
regulatory strategies for toxic substances. 4
There is now considerable evidence that substantial numbers
of human-made chemicals, many of them known toxicants, are pre-
sent in the bodies of United States citizens. In addition, these toxi-
cants are also highly likely to be present in the womb, and thus,
likely to be found in the bodies of developing fetuses and neonates.
The chemical contamination of a mother's body will in all likeli-
hood be shared with her child in utero or while nursing. Such expo-
sure to toxicants is often greater on a per-weight basis than a
mother's exposure to the same substances. Where there is compa-
rable exposure, adverse effects on children tend to be greater than
1. Previous versions of this Article were presented at the Southern California
Law and Philosophy Group, Villanova University Law School, Oxford University,
and the University of California Environmental Toxicology Program. They were
commented on by a number of colleagues to whom the Author is grateful: Tracey
Woodruff, Coleen McNamara, Stephen Munzer, Sharon Lloyd, Chris Naticchia,
Marshall Cohen, Craig Ihara, Matthew Liao, Julian Savalescu, David Eastmond,
and Mary Lyndon. The author is deeply grateful to Philippe Grandjean for an
invitation to the Faroe Islands Conference on Prenatal Programming and Toxicity
and for introducing him to these issues.
2. Carl Cranor is Professor of Philosophy at the University of California, River-
side. He specializes in philosophic issues arising at the interface of science and the
law. His books are two major publications on the subject. See CARL CRANOR, REGU-
LATING Toxic SUBSTANCES: A PHILOSOPHY OF SCIENCE AND THE LAW (Oxford Univ.
Press 1997) (1993); CARL CRANOR, Toxic TORTS: SCIENCE, LAW AND THE POSSIBILITY
OF JUSTICE (Cambridge Univ. Press 2007) (2006).
3. See THOMAS KUHN, THE ESSENTIAL TENSION: SELECTED STUDIES IN SCIENTIFIC
TRADITION AND CHANGE 233-37 (Univ. of Chi. Press 1977) (noting methodological
results of scientific developments).
4. As used in this Article, a "toxicant" is the toxicologists' preferred term for a
substance that is toxic. A "toxin" usually refers to poisons such as snake venom.
(251)
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in adults. Developing organ systems can be disrupted and perma-
nently damaged as a result of fetal and neonatal exposure to exoge-
nous insults. 5 In some cases, lifelong adverse effects will result.
Moreover, some diseases such as cancer are exacerbated or appear
sooner as a result of early exposures.
The main legal strategy for regulating toxicants in the United
States is by means of post-market laws, which allow substances to
enter the stream of commerce without required testing or agency
approval. If substances pose health problems, a government agency
must show harm or risks of harm to require regulation. These laws,
however, tend to function poorly in protecting adults from harmful
toxic effects. They will function much worse in the protection of
developing children. Under the existing United States laws which
apply to most substances, firms in effect have a right to expose
members of the public, particularly children, to toxicants until the
government satisfies a high scientific and legal burden of proof to
show that exposures cause harm or pose risks of harm. Such laws
can create serious health risks before toxicants are reduced or elim-
inated. The difficulties in identifying and controlling toxic sub-
stances result from the legal requirements of post-market laws. In
part, they rest on requirements to show harm or risks of harm to
developing children.
The above discussion highlights the need for a new regulation
model. This Article proposes that the United States move toward
either a "trespass" or a "permission" model for regulation. A tres-
pass model would hold chemical invasions in children or adults as
one kind of wrong with any resulting risks or harms viewed as addi-
tional wrongs. Firms seeking to market products should test sub-
stances to determine whether they can invade human
(mammalian) bodies and cross the placenta or be present in breast
milk. If they can, companies should further test them on non-
human systems to ensure, to the satisfaction of a government
agency, that products will not pose significant harms or risks of
harm to developing children. With a permission model, like the
European Union's REACH legislation, citizens have assurances,
based on non-human tests and certified by government agencies,
that products in the market will not pose harm or significant risks
5. As used in this Article, an "exogenous insult" refers to an insult from
outside the entity's body.
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of harm to adults or developing children. 6 As the aphorism
describing REACH puts it: No (safety) data, no market.
Some might not initially be persuaded of the need for a new
model for regulation. They should ask themselves whether they
want to bet the health of their children or their grandchildren on
post-market risk or harm-based legal structures. This is a dicey bet
to make. This Article argues that these laws function poorly in
preventing harm to developing children. Thus, this Article suggests
a new paradigm for the legal regulation of chemical substances that
can potentially invade human bodies, often exposing adults, devel-
oping fetuses, and newborns to health risks.
II. THE CENTERS FOR DISEASE CONTROL BIOMONITORING PROJECT:
THE PRESENCE OF CHEMICALS IN CITIZENS' BODIES
Recent studies conducted by the biomonitoring project at the
Center for Disease Control (CDC) have revealed that human bod-
ies contain varying levels of manmade environmental chemicals.
7
The CDC's aim is to measure the amount of a substance that can be
scientifically identified, and for which good exposure protocols can
be written to test for it in the blood and urine of a randomly se-
lected group of United States citizens in order to obtain some more
systematic information about human exposure."
The overall purpose of the research is to provide unique expo-
sure information to scientists, physicians, and health officials to
help prevent disease that results from exposure to environmental
chemicals. Specific public health uses of the exposure information
in the CDC's Report are:
* To determine which chemicals get into Americans and
at what concentrations.
o For chemicals with a known toxicity level, to determine
the prevalence of people with levels above those toxicity
levels.
6. See Registration, Evaluation, Authorization and Restriction of Chemicals
(REACH), No. 1907 (2006) (U.K.) (providing text of legislation establishing a Eu-
ropean Chemicals Agency).
7. Biomonitoring is "the direct measurement of people's exposure to toxic
substances in the environment by measuring the substances or their metabolites in
human specimens, such as blood or urine." See Dep't of Health and Human Servs.,
Ctrs. for Disease Control and Prevention, National Biomonitoring Program, http:/
/www.cdc.gov/biomonitoring/ (defining biomonitoring).
8. Dep't of Health and Human Servs., Ctrs. for Disease Control and Preven-
tion, Nat'l. Ctr. for Envtl. Health, Third National Report on Human Exposure to
Environmental Chemicals (Sept. 11, 2007), http://www.cdc.gov/exposurereport/
report.htm (stating project's goal).
253
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" To establish reference ranges that can be used by physi-
cians and scientists to determine whether a person or
group has an unusually high exposure.
" To assess the effectiveness of public health efforts to re-
duce exposure of Americans to specific chemicals.
" To determine whether exposure levels are higher
among minorities, children, women of childbearing
age, or other potentially vulnerable groups.
" To track, over time, trends in levels of exposure of the
population.
* To set priorities for research on human health effects. 9
The most recent CDC report on biomonitoring shows that
United States citizens' bodies contain at least 148 manmade sub-
stances.10 This raises some concern about their effects. A CDC re-
port due out in summer 2008 will show that approximately 270
substances can be measured in the human body."I This increase in
numbers does not mean that there are more substances in citizens'
bodies, but that more are now identifiable by reliable exposure
markers. As measurements are created, standardized, and com-
pleted, it seems highly likely that more substances will be found in
citizens' bodies. A Canadian report describing the results of testing
on eleven people found many chemicals in measurable levels in
their bodies. 12 Another recent report by the Body Burden Work
Group & Commonweal Biomonitoring Resource Center, which
conducted the biomonitoring of thirty-five ordinary citizens from
seven different states within the United States, found that all tested
positive for at least seven of twenty chemicals.' 3 Of these subjects,
thirty-three contained phthalates, all thirty-five had polybrominated
diphenyl ethers (a fire retardant in furniture and electronic equip-
9. DEP'T OF HEALTH AND HUMAN SERVS., CTRS. FOR DISEASE CONTROL AND PRE-
VENTION, THIRD NATIONAL REPORT ON HUMAN ExPosuRE TO ENVIRONMENTAL CHEM-
ICALS 3 (2005) [hereinafter REPORT ON HUMAN ExPosuRE], http://www.cdc.gov/
exposurereport/pdf/thirdreport.pdf (listing research's agenda).
10. Id. at 1-2 (providing list of chemicals).
11. Email from Larry Needham, Director of the Ctrs. for Disease Control Bi-
omonitoring Project (Sept. 10, 2007) (on file with author) (indicating that antici-
pated release date of next CDC biomonitoring report is summer of 2008).
12. ENVrL. DEF., TOXIC NATION: A REPORT ON POLLUTION IN CANADIANS 1
(Nov. 2005), http://www.toxicnation.ca/files/toxicnation/report/PATN-English.
pdf (detailing mix of toxic chemicals found in every person tested).
13. BODY BURDEN WORK GROUP & COMMONWEAL BIOMONITORING RES. CTR., Is
IT IN Us? CHEMICAL CONTAMINATION IN OUR BODIES: TOXIC TRESPASS, REGULATORY
FAILURE AND OPPORTUNITIES FOR ACTION 1-52 (2007) [hereinafter CHEMICAL CON-
TAMINATION], http://www.isitinus.org/documents/Is%201t%201n%2Us%2Re-
port.pdf (detailing study methods and findings).
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ment), and the thirty-three who provided urine samples had phtha-
lates and bisphenol A in their bodies. 14 The last three substances
are of substantial concern in the scientific community, but none
has received much regulatory attention.
The presence of manmade industrial chemicals in citizens'
bodies does not necessarily mean that they pose risks or are harm-
ful. Their mere presence is a wrong on a trespass model, and
should be viewed with concern. Moreover, there has not been ap-
propriate research on the effects of low levels of exposure and on
risks of harm to children or developing fetuses. As if to confirm
this point, an expert panel of the Food and Drug Administration
(FDA) recommended that the FDA recall cold and flu remedies for
young children on grounds that they did not seem to be effective
and that they had not been properly tested for use by children. 15
The CDC is careful about what it infers from the biomonitor-
ing. For example, with respect to one class of pesticides, the CDC
Report notes that "lt]he health effects of exposure to orga-
nochlorine pesticides on the general population at current levels of
exposure are unknown."' 6 The report contains similar comments
about many of the substances it considers; for some chemicals it
simply does not address this issue. 17 Yet, there are substances of
concern. Some are known or probable human carcinogens, some
are known or probable reproductive or developmental toxicants,
some are only possible toxicants, and some are perhaps unknown
for their toxicity, but are on the list simply because they are sus-
pected of posing risks to human health at certain concentration
levels.
14. Id. at 18 (providing results).
15. Gardiner Harris, Ban Sought on Cold Medicine for Very Young, N.Y. TIMES,
Sept. 29, 2007, available at http://www.nytimes.com/2007/O9/29/health/29fda.
html (describing ineffectiveness of cold medicines used in children as well as dan-
gers posed); Rob Stein, Cold Remedy Makers Pull Infant Medicines, WASH. POST, Oct.
11, 2007, available at 2007 WL 19957065 (describing movement to ban cold
medicines for children under six); Gardiner Harris, Makers Pull Infant Cold
Medicines, N.Y. TIMES, Oct. 11, 2007, available at http://www.nytimes.com/2007/
10/11/health/l cnd-cold.html?hp (describing voluntary withdrawal of cold
medicines from market); Editorial, Children and Cold Medicines, N.Y. TIMES, Nov. 3,
2007, available at http://www.nytimes.com/2007/11/03/opinion/03sat3.html
(describing efforts on part of drug companies to soften impact of negative
studies).
16. See REPORT ON HUMAN ExposuRE, supra note 9, at 309 (describing orga-
nochlorine pesticides).
17. See id. (discussing other chemicals).
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III. RISKS TO FETUSES AND INFANTS
A. Women's Chemical Contamination Will Be Shared with
Developing Fetuses and Nursing Newborns
As already noted, many substances that are in a woman's body
will be transmitted to the unborn fetuses or to newborns that are
being nursed.1 8 Some might have thought that the womb is a shel-
tered, capsule-like environment safe from the intrusions and dan-
gers of the outside world. Apparently, this was a widely accepted
view until the mid-1960s. As Needleman and Bellinger wrote in
1995:
Only three decades ago, the prevailing image of the womb
was that of a time capsule with a short lease, relatively im-
permeable to circulating drugs or toxicants. The mother's
body was considered an altruistic reservoir, prepared to
sacrifice itself to the fetus's sustenance.1 9
Moreover, the layer of biological material known as the placenta
was once was called "the placental barrier because at one time it was
believed to afford great protection to the embryo and fetus. [Scien-
tists] now know that the degree of protection is often modest at
best, and that instead of being a barrier, the placental membrane
acts more as an ultrafilter."20 In the 1960s, children born to women
exposed to methyl mercury and thalidomide raised the first
alarms. 21 Female fetuses' exposure to diethylstilbestrol in the
womb was soon found to cause various reproductive tract cancers
when the women reached their early twenties. 22 Subsequently, to-
18. Philippe Grandjean et al., The Faroes Statement: Human Health Effects of De-
velopmental Exposure to Chemicals in Our Environment, 102 BASIC & CLINICAL PHARMA-
COLOGY & TOXICOLOGY 73, 74 (2007), available at http://www.blackwell-synergy.
com/doi/pdf/10.1111/j.1742-7843.2007.00114.x (describing susceptibility of in-
fants to toxic exposure).
19. HERBERT L. NEEDLEMAN & DAVID BELLINGER, PRENATAL EXPOSURE TO Toxi-
CANTS ix (Herbert L. Needleman & David Bellinger eds., Johns Hopkins Univ.
Press 1994) (describing outdated views on susceptibility of infants in womb to toxic
substances). A similar view was reported to this Author by Prue Talbot, a Univer-
sity of California, Riverside, developmental biologist.
20. RONALD D. HOOD, PRINCIPLES OF DEVELOPMENTAL TOXICOLOGY REVISITED,
DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY. A PRACTICAL APPROACH 8 (Ron-
ald D. Hood ed., CRC Press 2d ed. 2006) (introducing fundamental toxicology
concepts). See generally E.M. FAUSTMAN & P. RIBEIRO, PHARMACOKINETIC CONSIDERA-
TIONS IN DEVELOPMENTAL TOXICrIY, DEVELOPMENTAL TOXICITY: RiSK ASSESSMENT AND
THE FUTURE (Ronald D. Hood ed., 1990).
21. See NEEDLEMAN & BELLINGER, supra note 19, at ix (positing the event that
brought attention to effects of toxicity to infants in womb).
22. JAMES L. SCHARDEIN & OREST T. MACINA, HUMAN DEVELOPMENTAL ToxI-
CANTS: ASPECTS OF TOXICOLOGY AND CHEMISTRY 286-87 (CRC Press 2007) (detailing
6
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bacco smoke, alcohol, polychlorinated biphenyls, vitamin A, and
numerous other drugs and chemicals have been identified as pos-
ing risks of harm. A recent textbook author states that "[i]t is
clearly evident that there really is no placental barrier per se: The
vast majority of chemicals given the pregnant animal (or woman)
reach the fetus in significant concentrations soon after
administration." 23
Whether a given substance will pass through the placenta de-
pends on a variety of factors, including its molecular size (the
smaller, the more likely), its charge (uncharged molecules more
readily cross), its fat solubility (the more soluble, the more likely to
cross), its degree of ionization (the less ionization, the more likely
to cross), and its molecular complexity (the less complex, the more
likely to cross). 24 There are a number of developmental toxicants,
so classified by different authors or agencies for different
purposes. 25
Developmental toxicologists classify adverse developmental ef-
fects into four categories: "death [of the fetus], malformation,
growth retardation, and functional deficit."26 Fetal death or mal-
formations tend to be obvious, although the cause may not be clear,
but growth retardation and the various kinds of functional deficits
are more subtle, consequently being more difficult to detect and to
ascribe causation.
At a recent scientific conference in the Faroe Islands, scientists
presented results of the current understanding of the effects of
a wide range of reproductive problems in males and females with DES intake dur-
ing pregnancy); see also Sindell v. Abbott Labs., 607 P.2d 924, 926 (Cal. 1980)
(describing danger of DES).
23. JAMES L. SCHARDEIN, CHEMICALLY INDUCED BIRTH DEFECTS 5 (Marcel Dek-
ker, Inc. 3d ed. 2002) (rejecting notion of placental barrier with respect to most
chemicals).
24. HOOD, supra note 20, at 8-9 (discussing factors influencing whether pla-
cental barrier allows chemical passage).
25. See Philippe Grandjean & Phillip J. Landrigan, Developmental Neurotoxicity
of Industrial Chemicals, 368 LANCET 2167, 2168-72 (2006) (estimating 200 neurotoxi-
cants alone based only upon human studies); JAMES L. SCHARDEIN & OREST T.
MACINA, Preface to HUMAN DEVELOPMENTAL ToxICANTS: ASPECTS OF TOXICOLOGY
AND CHEMISTRY (Taylor & Francis 2007) (estimating that there are about 70 devel-
opmental toxicants and reviewing 50 present developmental toxicants arbitrarily
selected based upon their commercial impact on public health considerations,
availability of quality data in humans and animals, and representations of various
classes of development toxicity).
26. See KIM N. DIETRICH & DAVID BELLINGER, Assessment of Neurobehavioral Devel-
opment in Studies of the Effects of Prenatal Exposure to Toxicants, in PRENATAL ExPoSURE
TO TOxICANTS: DEVELOPMENTAL CONSEQUENCES 57 (H. L. Needleman & D. C. Bel-
linger eds., Johns Hopkins Univ. Press 1994) (identifying four classifications for
adverse developmental effects).
257
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chemical pollutants on human fetal and mammalian developmen-
tal processes. 27 The conference results were summarized as follows:
Three aspects of children's health are important in con-
junction with developmental toxicity risks. First, the
mother's chemical body burden will be shared with her
f[]etus or neonate, and the child may, in some instances, be
exposed to larger doses relative to the body weight. Second,
susceptibility to a wide range of adverse effects is increased during
development, from preconception through adolescence,
depending on the organ system. Third, developmental
exposures to [toxicants] can lead to life-long functional defi-
cits and manifestations of increased disease [risks].28
In utero exposure to pollutants can yield adverse consequences
over a lifetime. 29 Animal studies show that changes produced dur-
ing development can be permanent and in some cases transmitted
to later generations. 30 There is some evidence for similar long-term
consequences in humans.3 One dramatic example involves prena-
tal exposure to diethylstilbestrol (DES), which caused cancer in fe-
male children twenty years after birth, and now appears to affect
male offspring by causing genital abnormalities.3 2 Other long-term
effects may be far more subtle and more difficult to detect. An-
other very recent study found that:
High levels of serum p,p'-DDT predicted a statistically sig-
nificant 5-fold increased risk of breast cancer among wo-
men who were born after 1931. These women were under
14 years of age in 1945, when DDT came into widespread
use, and mostly under 20 years as DDT use peaked. Wo-
men who were not exposed to p,p'-DDT before 14 years of
27. See Prenatal Programming and Toxicity, Conference Programme (May 20-
24, 2007), http://www.pptox.dk/Programme/tabid/68/Default.aspx (discussing
susceptibility of fetal life and early infancy to environmental hazards).
28. See Grandjean, supra note 18, at 74 (emphasis added) (discussing effects
of toxicants on developing human being).
29. See id. (summarizing aspects of toxicity to children).
30. See Grandjean & Landrigan, supra note 25, at 2168 (discussing animal
studies).
31. See id. (discussing identification of neurological developmental problems
in humans).
32. See SCHARDEIN & MACINA, supra note 22, at 287 (noting wide range of re-
production and developmental problems associated with pregnant intake of DES).
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age showed no association between p,p'-DDT and breast
cancer . .
Consequently, since women heavily exposed to DDT have not
yet reached the age of fifty, the public health significance of their
exposure may be quite large.3 4 In addition, recent studies suggest
that lead exposure early in life can contribute to neurological de-
generation late in life, "a proportion of what has been termed 'nor-
mal' age-related cognitive decline may, in fact, be due to exposure
to neurotoxicants such as lead. ' 35 The lead content in the bodies
of persons may exacerbate such neurogenerative conditions as
Alzheimer's disease, Parkinson's disease, and Lou Gehrig's
disease. 36
Moreover, as the Faroe's Statement emphasizes, children ex-
posed in utero or during the immediate postnatal period may be
much more susceptible to toxic insults than mature adults.3 7 There.
are a variety of reasons for this, which will be discussed below.
Finally, once children are born and begin their own lives
outside the womb, they will be subjected to most of the same toxic
insults and invasions that adults are. Consequently, children have
at least three major routes of exposures: (1) in the womb, (2)
through nursing, and (3) from general environmental exposures
following birth.
B. Developing Children Often Experience Greater Exposures
As the Faroe's Statement indicates, toxicants can concentrate
in placental cord blood, increasing toxic concentrations in a devel-
oping fetus to higher levels than in the mother's body tissues.
3 8 If
newborns are breast-fed, any toxicants that are lipophilic or soluble
in body fats can have greater concentrations in breast milk than in
33. Barbara A. Cohn et al., DDT and Breast Cancer in Young Women: New Data on
the Significance of Age at Exposure, 115 ENvTL. HEALTH PERSPECTIVES 1406, 1406
(2007) (noting results of DDT exposure investigation forecasting predictably of
cancer, specifically focusing on young women exposed during peak of DDT
usage).
34. See id. (noting danger of DDT exposure and future consequences).
35. See Brian S. Schwartz & Walter F. Stewart, Lead and Cognitive Function in
Adults: A Questions and Answers Approach to a Review of the Evidence for Cause, Treat-
ment, and Prevention, 19 INT'L REv. OF PSYCHIATRY 671, 671 (2007) (noting potential
link between lead and neurodegenerative disease).
36. See id. at 685 (noting potential for exacerbating well-recognized neurolog-
ical diseases of old age).
37. See Grandjean, supra note 18, at 73 (noting increased risk of harm from
exposure in children).
38. See id. (finding developing fetus' concentration of toxicants can reach
higher levels than their mother's).
9
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the nursing mother's body. Toxicants in breast milk can be as
much as one hundred times more concentrated than in the
mother's body.39 A toxic substance, such as lead, that is in the
bones of a mother's body can be mobilized by the same processes
that mobilize calcium for nursing (the "calcium stream"), resulting
in substantial concentrations to nursing infants. 40
Newborns and small children have a number of features that
can increase their exposures to toxicants. They have higher metab-
olisms and breathing rates, 41 as well as "augmented absorption
rates, and diminished ability to detoxify many exogenous com-
pounds, relative to that of adults. '42 Behaviorally, they tend to play
close to the floor, increasing exposure to toxicants present in their
environment. The pesticide Chlorpyrifos, for example, can be
found in carpeting exposing children who play there. In addition,
children tend to "mouth" most objects in their environment, to be
more active, and to have higher fluid and food intake rates relative
to their body weight than adults. 43
This is merely a sketch of some of the differences, but it indi-
cates that developing fetuses and newborns have a number of physi-
ological and behavioral characteristics that can increase their
exposures to any toxicants.
C. Developing Children Often Have Greater Susceptibility
Developing fetuses, newborns, and young children exposed to
low levels of toxicants tend to be more susceptible to adverse effects
than older children or adults subject to the same exposure. For
example, the blood-brain barrier that normally protects adults by
keeping many exogenous toxicants out of the brain does not de-
39. See Grandjean & Landrigan, supra note 25, at 2168 (finding maternal
breast milk passes lipophilic substances to infant at over 100 times mother's own
concentrations).
40. David Bellinger & Herbert L. Needleman, The Neurotoxicity of Prenatal Ex-
posure to Lead: Kinetics, Mechanism and Expressions, in PRENATAL ExPosURE TO Toxi-
CANTS 91-92 (Herbert L. Needleman & David Bellinger eds., Johns Hopkins Univ.
Press 1994) (stating risk of breastfeeding children by mothers whose bodies are
contaminated by toxicants, including lead).
41. See Mark D. Miller et al., Differences Between Children and Adults: Implications
for Risk Assessment at Calfornia EPA, 21 INT'L J. TOXICOLOGY 403, 406 (2002) (re-
porting that higher metabolism and breathing rates in children make them more
susceptible to toxicants).
42. See Grandjean & Landrigan, supra note 25, at 2168 (finding children are
less able than adults to detoxify foreign substances).
43. See Miller et. al., supra note 41, at 405 (identifying greater susceptibility of
children to toxicants than adults).
10
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velop in children until about six months of age. 4 4 Moreover, the
"brain continues to change throughout life . . . with possible age-
specific periods of susceptibility to neurotoxicants. ''45 Conse-
quently, any toxicants in the mother's body that cross the placenta
and invade the womb will expose the developing fetus and may not
be prevented from entering the brain because the blood-brain bar-
rier is not yet effectively functional.
In general, a developing child's susceptibility to a wide range
of adverse effects is increased during development, from precon-
ception through adolescence, depending on the organ system. A
textbook on developmental toxicity describes this point as follows:
Organisms tend to be significantly more sensitive to many
adverse environmental influences during early develop-
mental stages, although this differential may not be quite
as universally applicable in mammals as was once thought
.... Many tissues are undergoing rapid cell division, and
the embryo, and to a considerable extent, the fetus, has
much less capacity to metabolize xenobiotics than does
the adult.46
Moreover, "[t]he toxicology and pharmacology literature docu-
ments that children often react quantitatively and/or qualitatively
differently to many toxins and drugs as compared to adults. In
most organ systems, these differences amount to an increased sus-
ceptibility to many hazardous environmental chemicals. ' 47 Adverse
developmental effects in several organ systems illustrate this
vulnerability.
[For example, t]he developing human brain is inherently
much more susceptible to injury caused by toxic agents
than is the brain of an adult. This susceptibility stems
from the fact that during the 9 months of prenatal life, the
human brain must develop from a strip of cells along the
dorsal ectoderm of the fetus into a complex organ consist-
ing of billions of precisely located, highly interconnected,
44. See Grandjean & Landrigan, supra note 25, at 2168 (stating blood-brain
barrier does not develop in children until six months after birth).
45. See Schwartz & Stewart, supra note 35, at 672 (explaining that changes in
brain continue for life).
46. HOOD, supra note 20, at 7 (stating that there are greater risks to mammals
during developmental stages of life).
47. Luz Claudio et al., Testing Methods for Developmental Neurotoxicity of Environ-
mental Chemicals, 164 ToxICOLOGY & APPLIED PHARMACOLOGY 1, 2 (2000) (finding
children often react to toxicants differently than adults).
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and speciali[z]ed cells. Optimum brain development re-
quires that neurons move along precise pathways from
their points of origin to their assigned locations, that they
establish connections with other cells, both nearby and
distant, and that they learn to communicate with other
cells via such connections. All these processes have to take
place within a tightly controlled time frame, in which each
developmental stage has to be reached on schedule and in
the correct sequence. Because of the extraordinary com-
plexity of human brain development, windows of unique
susceptibility to toxic interference arise that have no coun-
terpart in the mature brain, or in any other organ. If a
developmental process in the brain is halted or inhibited,
there is little potential for later repair, and the conse-
quences can therefore be permanent.48
Moreover, the brain has reduced capacity to repair damage. 49
The immune system is similar to the brain in the precise, se-
quential nature of development and potential sensitivity to exoge-
nous insults:
The development of the immune system results from a se-
ries of carefully timed and coordinated events during em-
bryonic, fetal, and early postnatal life. There is evidence
for a number of immunotoxic chemicals that exposure of
pregnant animals at doses causing only transient effects in
adults produces long-lasting or permanent immune defi-
cits in their offspring. During critical developmental
stages, the future immune system cells are increasing in
number and becoming specialized in function.50
The development of the immune system goes through several
"discrete functional changes representing critical windows of differ-
ential vulnerability to toxicants."51 First, "early-life stages have in-
48. See Grandjean & Landrigan, supra note 25, at 2167-68 (observing complex-
ity of brain's sensitive development state). See generallyJ. Dobbing, Vulnerable Peri-
ods in Developing Brain, in APPLIED NEUROCHEMISTRY 287-316 (A. N. Davidson &J.
Dobbing eds., 1968); P. M. Rodier, Developing Brain as a Target of Toxicity, 103
ENXcrL. HEALTH PERSP. 73, 73-76 (1995); D. Rice & S. Barone, Jr., Critical Periods of
Vulnerability for the Developing Nervous System: Evidence from Humans and Animal Mod-
els, 108 ENWrL. HEALTH PERSP. 511, 511-33 (2000).
49. See Miller et. al., supra note 41, at 413 (explaining brain's reduced capacity
to repair damage during developmental stage).
50. See id. at 411 (describing developmental growth of immune system).
51. See Rodney R. Dietert & Michael S. Piepenbrink, Perinatal Immuniotoxicity:
Why Adult Exposure Assessment Fails to Predict Risk, 114 ENrTL. HEALTH PERSP. 477,
12
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creased dose sensitivity to most toxicants."5 2 This has been well
documented for lead, dioxin, and mercury.53 Second, toxicants
that adversely affect the developing immune system produce "a dif-
ferent and unpredictable array of alterations when the exposure oc-
curs in utero or in the early neonate versus the adult. ' 54 Lead,
methoxychlor, ethanol, and genistein, among others, illustrate this
point. Third, alterations in the immune system following early ex-
posure can cause persistent changes that show up later in life, as
occurred, for example, with DES. Finally, "sublethal exposure to a
toxicant may produce an unrecognizable immunotoxic alteration
until the postnatal immune system is placed under subsequent
stress." 55 DES and lead have caused such stress resulting in adverse
effects. Thus, the assessment of risks in adults does not predict per-
inatal sensitivity to toxicants. In addition, as long as the immune
system is immature or partially disabled because of any adverse tox-
icity effects, it will be unable to fully protect other organ systems
from toxic insults.
Lung development goes through a long process that can be
subject to external insults and perturbations along the way. One
researcher has called attention to these issues as follows:
The developing lung is highly susceptible to damage from
exposure to environmental toxicants particularly due to
the protracted maturation of the respiratory system, ex-
tending from the embryonic phase of development in
utero through to adolescence. The functional organiza-
tion of the lungs requires a coordinated ontogeny of criti-
cal developmental processes that include branching
morphogenesis, cellular differentiation and proliferation,
alveolarization, and maturation of the pulmonary im-
mune, vasculature, and neural systems. Therefore, expo-
sure to environmental pollutants during crucial periods of
prenatal and/or postnatal development may determine
the course of lung morphogenesis and maturation. De-
477 (2006) (describing various stages of immune system development). See gener-
ally R. R. Dietert et al., Workshop to Identify Critical Windows of Exposure for Children's
Health: Immune and Respiratory Systems Work Groups Summary, 108 ENVTL. HEALTH
PERSP. 483, 483-90 (2000).
52. See Dietert & Piepenbrink, supra note 51, at 480 (discussing how dose
levels impact perinatal immunotoxic sensitivity).
53. See id. (noting dose sensitivity to several different toxicants).
54. See id. (discussing how toxicants can adversely affect developing immune
systems and produce unpredictable alterations).
55. See id. (describing latency).
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pending on the timing of exposure and pathobiological
response of the affected tissue, exposure to environmental
pollutants can potentially result in long-term alterations
that affect the structure and function of the respiratory
system.
Besides an immature respiratory system at birth, children
possess unique differences in their physiology and behav-
ioral characteristics compared to adults that are believed
to augment the vulnerability of their developing lungs to
perturbations by environmental toxins. Furthermore, an
interaction between genetic predisposition and increased
opportunity for exposure to chemical and infectious dis-
ease increase the hazards and risks for infants and
children. 56
Ozone, environmental tobacco smoke and particulate matter are
substances that pose special risks to the developing lung.
Finally, the reproductive system develops, not only in utero, but
throughout childhood and puberty. During this long period there
are a variety of opportunities for toxicant exposure to interfere with
development.
Because the reproductive process is critical for perpetua-
tion of any species of organisms, factors or agents that al-
ter or disrupt this process can have devastating
consequences.
We now realize that such agents can arise from varying
sources-which can be pharmacological, environmental,
and natural-having extensive chemical structural diver-
sity. In addition, the effects can be through a single ac-
tion, or in combination, and can influence either
individual or multiple cellular signaling pathways in a tis-
sue or organ system. As such, it is difficult to ascribe a
single action or effect to certain agents ....
Most important in recent toxicology studies is the number
of examples showing that exposure during specific periods
of development results in long-term effects that occur fol-
lowing sexual maturity and adulthood. Certain organ sys-
tems are more susceptible to toxicants during these
56. Radhika Kajekar, Environmental Factors and Developmental Outcomes in the
Lung, 114 PHARMACOLOGY & THERAPEu-rIcs 129, 129 (2007) (discussing interaction
between genetic predisposition and increased opportunity for exposure to chemi-
cals and infectious diseases).
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developmental periods. It is extremely important to real-
ize that not only adults, but also children, infants, and the
developing fetus, are potential targets for toxicological in-
sult. Exposure during these sensitive periods either alters
normal development, resulting in immediate or acute ef-
fects, or may subsequently compromise normal physiology
and function later in life.57
D. Specific Substances Can Cause Adverse Effects During
Development
Apart from general biological reasons and background evi-
dence about the vulnerability of developing organ systems, some
particular substances have been identified as causing specific ad-
verse effects. 58 For instance, exposures to comparatively high doses
of dioxins have altered pigmentation, been associated with develop-
mental delays and lower IQs, have caused cognitive delays, and have
probably affected sex-related behaviors, with none of the effects be-
ing reversible. 59 PCB exposures can also result in male deficits in
spatial reasoning, lack of endurance, clumsy movement, and IQs
approximately six points lower at age eleven. 60 Children have
greater susceptibility prenatally than during the immediate postna-
tal period.61  Background levels of dioxins "can influence the
human immune system. 62
Taken together, the human studies involving complex
mixtures of dioxin-like compounds, including both dioxin
and non-dioxin-like PCBs, suggest that levels present in
the general population may be associated with subtle signs
of neurological dysfunction, delays in psychomotor devel-
57. Kenneth S. Korach, Preface, in REPRODUCTIVE AND DEVELOPMENTAL Toxi-
COLOGYV (Kenneth S. Korach ed., Marcel Dekker Inc. 1998) (noting how exposure
to toxicants during sensitive periods either alters normal development or subse-
quently compromises normal physiology).
58. See id. (identifying various sources causing adverse effects).
59. Linda Birnbaum, Developmental Effects of Dioxins, in REPRODUCTIVE AND DE-
VELOPMENTAL TOXICOLOGY 103 (Kenneth S. Korach ed., Marcel Dekker Inc. 1998)
(discussing impact of exposures to comparatively high doses of dioxins).
60. Grandjean & Landrigan, supra note 25, at 2172 (noting role that PCB
exposures can have in certain male deficits).
61. Joseph L. Jacobson & Sandra W. Jacobson, The Effects of Perinatal Exposure
to Polychlorinated Biphenyls and Related Contaminants, in PRENATAL ExPosuRE TO Tox-
ICANTS 144 (Herbert L. Needleman & David Bellinger eds., Johns Hopkins Univ.
Press 1994) (discussing how prenatal children have greater susceptibility than post-
natal children).
62. See Birnbaum, supra note 59, at 105 (discussing how background levels of
dioxins influence human immune system).
265
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opment, alterations in thyroid hormone status, and
changes in immunological functions.63
Recent research suggests that PCB exposures also skew sex ratios in
newborns among the Inuits and other groups inhabiting the North-
ern Hemisphere. 64 Traditionally, out of one hundred births, 51 will
be boys and 49 girls; in the high northern latitudes researchers are
finding that females are born at twice the rate of males.65
A great deal of research has been done on lead, and the results
are both revealing and disturbing. Lead, now a ubiquitous metal
widely detected in the environment, is toxic to most living things.66
Its toxic effects "were known in Roman times .... In the 1940s...
acute [exposures caused] severe learning and behavioral
problems."67 Lead exposure can cause both clinically identifiable
and more subtle adverse effects. Most sensitive is the nervous sys-
tem, but other target organs include the gastrointestinal tract, re-
productive system, and skeletal system. 68 The first toxic effects of
lead were noticed following substantial exposure levels, but over
time researchers found much lower concentrations of lead may
cause diseases or functional deficiencies. 69 Consequently, the
United States Environmental Protection Agency (EPA) has set a cap
at 151.tg of lead per liter in drinking water with an action level of 10
gg/dL (micrograms /deciliter) adopted by the CDC for children.70
There is considerable evidence that umbilical cord blood levels
(thus, prenatal exposures) in excess of 10 gg /dL cause delays in
early cognitive development and remain persistent when blood lead
63. See id. at 106 (discussing results from human studies involving complex
mixtures of dioxin-like compounds).
64. Francesca Lyman, Are Boys An Endangered Species?, http://www.b-e-a-c-
h.org/news%20images/Are%2OBoys%2OAn%2OEndangered%20Sp.pdf 1-2 (dis-
cussing suggestion that PCB exposures skew sex ratios in newborns).
65. Id. (providing information on population in Arctic Circle).
66. Robert A. Goyer & Thomas W. Clarkson, Toxic Effects of Metals, in
CAsaRETr AND DouL's TOxiCOLOGy 623, 639 (4th ed. 1991) (noting that lead is
toxic to most living organisms).
67. Grandjean & Landrigan, supra note 25, at 2169 (discussing when toxic
effects of lead became known to humans).
68. See Goyer, supra note 66, at 641 (noting target organs of human body).
69. Grandjean & Landrigan, supra note 25, at 2169-70 (discussing effects of
lead on humans).
70. Dep't of Health and Human Servs., Agency for Toxic Substances & Dis-
ease Registry, Lead Toxicity What Are U.S. Standards for Lead Levels?, http://
www.atsdr.cdc.gov/csem/lead/pb_standards2.html (setting drinking water
standards).
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levels remained above 10 gg /dL. 7' In addition, fetal exposures are
more harmful than postnatal exposures. 72 More recent research
suggests that there is likely no threshold for adverse effects from
childhood lead poisoning.73 Moreover, researchers found that chil-
dren are much more sensitive to blood lead levels than adults, al-
though some recent research suggests that even adults can be
harmed at fairly low exposures, causing concern for occupationally
exposed individuals. 74 Finally, exposures to lead early in life appear
to contribute to "'normal' age-related cognitive decline[s] . .
later in life. 75 Beyond the specific substances just noted, Grandjean
and Landrigan have summarized the scientific literature finding
about 200 neurotoxic development toxicants based solely on
human studies.76
E. Particular Diseases Can Be Exacerbated by Exposures During
Development
Particular diseases can be exacerbated as a result of in utero,
immediate postnatal, or childhood exposure to toxicants. Consider
cancers as one such example. There has been a general increase in
childhood cancers since the 1970s that researchers indicate may
not be due merely to improved diagnosis of the disease. 77 Moreo-
ver, there is a documented increased risk of cancer as a result of
DES exposure, as well as "higher rates of radiation-induced breast
cancer among women exposed during puberty, compared with
those exposed after puberty .... -"7 For women, exposure to to-
71. David Bellinger & Herbert L. Needleman, supra note 40, at 89 (finding
children with high umbilical cord blood levels achieved lower Mental Develop-
ment Index scores).
72. Id. at 104 (stating difference between post-natal and fetal lead exposure).
73. See Richard L. Canfield et al., Low-Level Lead Exposure and Executive Func-
tioning in Young Children, 9 CHILD NEUROPSYCHOLOGY 35, 35-53 (2003) (concluding
lead exposure places children at disadvantage in associative learning and academic
success); see also David Bellinger & Herbert L. Needleman, Intellectual Impairment
and Blood Lead Levels, 349 NEW ENG. J. MED. 500, 500 (Jul. 2003) (concluding there
are extensive adverse effects of lead poisoning).
74. Ellen K Silbergeld & Virginia M. Weaver, Exposures to Metals: Are We Protect-
ing the Workers?, 64J. OCCUPATIONAL & ENVrL. MED. 141, 141-42 (Mar. 2007) (show-
ing harmful effects of lead in adults).
75. Schwartz & Stewart, supra note 35, at 671 (indicating cognitive decline
may be due to exposure to neurotoxicants).
76. Grandjean & Landrigan, supra note 25, at 2175 (finding over two hundred
chemicals known to cause neurotoxic effects in humans).
77. Miller, supra note 41, at 411-12 (concluding increased cancer levels may
not be function of better testing).
78. Id. at 412 (citing NRC Report describing effects of radiation during pu-
berty). See generally NATIONAL RESEARCH COUNCIL, HEALTH EFrEcrs OF ExPosuRE
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bacco smoke during puberty may increase the risk of breast cancer
among those with certain gene-based physiological characteristics.7 9
The effect of women's exposure to DDT during adolescence ap-
pears to hasten the onset of breast cancer.80 Finally, there is sub-
stantial evidence among experimental animals (our mammalian
relatives) of increased cancer risks following early life exposures to
a number of compounds such as urethane, vinyl chloride, DES,
tamoxifen, nitrosourea compounds and alkenylbenzene com-
pounds,8' as well as aspartame.8 2 EPA funded research supports
the finding that animal exposures to mutagenic carcinogens "indi-
cate a 5- to 60-fold increased carcinogenic sensitivity in the . . ."
immediate postnatal period and a somewhat similar but smaller in-
crease for exposures to radiation, but there is no such effect for
carcinogens that depends upon metabolic activation (in part be-
cause the metabolic processes for reducing compounds is less devel-
oped in immature mammals).83
Additionally, in some cases children either develop diseases or
adverse conditions not seen in adults at the same exposure levels,
or adverse effects in children are worse than the same disease in
adults, or the disease may emerge earlier.8 4 Early exposures can
lead to life-long adverse effects, especially neurological effects.85 In
some cases exposure may even result in late-life adverse function-
ing, on the hypothesis that subclinical injuries "silently kill a frac-
tion of the cells needed to sustain brain function in later life (e.g.,
in the substantial nigra).' '86 Prenatal exposures to lead, tobacco
smoke, and pesticides are associated with poor cognitive function-
TO Low LEVELS OF IONIZING RADIATION: BEIR V (1990) available at http://www.nap.
edu/openbook.php ?record-id=1224&page=RI
79. Miller, supra note 41, at 411-12 (finding tobacco smoke increases risk of
breast cancer).
80. Cohn, supra note 33, at 1413 (discovering early life exposure to DDT may
increase breast cancer risk).
81. See Miller, supra note 41, at 411-12 (finding increased cancer risk in nu-
merous compounds).
82. Morando Soffritti et al., Life-Span Exposure to Low Doses of Aspartame Begin-
ning during Prenatal Life Increases Cancer Effects in Rats, 115 ENVTL. HEALTH PERSP.
1293, 1293-97 (2007) (finding carcinogenic effects of aspartame in animals after
prenatal exposure).
83. Dale Hattis et al., Age-Related Dfferences in Susceptibility to Carcinogenesis: A
Quantitative Analysis of Empirical Animal Bioassay Data, 112 ENVrL. HEALTH PERSP.
1152, 1152 (2004) (showing increased carcinogenic sensitivity in fetal period).
84. See Grandjean & Landrigan, supra note 25, at 2169-73 (finding effects of
lead, methyl mercury, ethanol, toluene, and perchlorate on children).
85. Id. at 2174 (discussing effects of early exposure to toxicants).
86. Id. (discussing effects of exposure in later life).
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ing, attention deficit hyperactivity disorder, antisocial activity,8 7 and
exacerbated neurogenerative diseases late in life. 88 This evidence
leads scientists to propose that low level perinatal exposures may
represent "a silent pandemic in modern society."8 9
The above findings led the scientists at the Faroe Island Con-
ference to adopt the view that, for children exposed prenatally and
during the immediate postnatal period, the timing of a dose may be
as important as the particular amount of a dose. 90 An important
assumption of toxicology has been that "the dose makes the
poison."91 For developmentally linked effects, however, it appears
that "the timing makes the poison. ' 92 Ill-timed and even very low
exposures can be harmful.
F. Scientific Summary
The scientific picture that emerges from the above review is
incomplete in some respects, but compelling nonetheless. As a
matter of general knowledge scientists know that developing organ
systems in mammals, including humans, are more susceptible to ad-
verse effects from toxicants. Developing fetuses and children often
have greater exposures on a per body weight basis than adults,
higher metabolisms, breathing rates, and absorption rates along
with behavioral tendencies increasing exposures. At the same time,
developing children have fewer defenses against potential toxicants
than mature adults. Moreover, there is compelling evidence that
particular compounds, such as lead, mercury, DES, pesticides, and
radiation have substantial adverse effects on developing humans
and animals. Some diseases are exacerbated or triggered sooner as
a result of early exposures. Early prenatal or neonatal exposures
may cause adverse effects much later in life.93
87. BRUCE LANPHEAR ET AL., CINCINNATI CHILDREN'S Hosp. MED. CTR. & UNV.
OF CINCINNATI, ROLE OF ENVIRONMENTAL TOXICANTS IN THE DEVELOPMENTAL ORI-
GIN OF LEARNING AND BEHAVIOURAL PROBLEMS 1 (May 21, 2007), http://www.pptox.
dk/portals/0/o6.pdf (reporting neurological risks associated with prenatal expo-
sure to lead, tobacco smoke, and other toxicants).
88. Schwartz & Stewart, supra note 35, at 682-83 (discussing exacerbation of
neurogenerative diseases from exposure).
89. See Grandjean & Landrigan, supra note 25, at 2174 (arguing that evidence
suggests that low level prenatal and perinatal exposures to industrial chemicals
have created a silent pandemic of neurological disorders).
90. See Grandjean et al., supra note 18, at 74 (discussing conclusions).
91. Id. (discussing paradigm developed by Paracelsus).
92. Id. (suggesting when exposure occurs is quite important in causing toxic
effects perinatally).
93. Id. (suggesting that early prenatal exposure can likely lead to later
effects).
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Nonetheless, there are gaps in the science. The evidentiary
picture may be something like a pointillist painting with parts of the
picture filled in with some data points, other parts blank, but the
general background reasonably solid. Scientists almost certainly do
not yet know all the compounds that might have such adverse ef-
fects and may never have an exhaustive list, because new develop-
mental toxicants are likely to be to be discovered. They may not yet
know all the disease processes that can be accelerated or exacer-
bated by early exposures to toxicants. They may not know the low-
est exposures during development that can pose adverse effects,
either immediately or later in life. The resulting picture is troub-
ling, however. There is substantial scientific concern that sub-
stances remarkably similar to those with known toxicity are only
now being appropriately appreciated, such as polybrominated di-
phenyl ethers, Bisphenol A and phthalates.94
Just because there are gaps in the scientific picture, should we
be willing to bet our children will be safe in the future from adverse
effects? This is a poor bet. Do we want to bet that the currently
incomplete picture means the country need not take steps to better
protect our children's health? This too would be a poor bet.
Polybrominated diphenyl ethers (PBDEs), illustrate the man-
ner in which the science of toxicants emerges (although in some
respects the science is much better for this class of products than
for many because of similarities to known toxicants). The PBDE
example also shows the difficulties of using post-market laws to reg-
ulate substances to which children will be exposed in the womb and
early in life.
94. Kim Hooper & Thomas A. McDonald, The PBDEs: An Emerging Environmen-
tal Challenge and Another Reason for Breast-Milk Monitoring Programs, 108 ENVTL.
HEALTH PERSP. 387, 387-88 (2000) (discussing scientific concern that persistent
organic pollutants with known toxicity are only now being appropriately appreci-
ated); see also Lucio G. Costa & Gennaro Giordano, Developmental Neurotoxicity of
Polybrominated Diphenyl Ether (PBDE) flame Retardants, 28 NEURoToxICOLOGY 1047,
1047-67 (2007) (discussing scientific concern that toxicity of PBDEs are only now
being appropriately appreciated); Prasada Rao S. Kodavanti, Neurotoxicity of Persis-
tent Organic Pollutants: Possible Mode(s) of Action and Further Considerations, 3 DOSE-
RESPONSE 273, 273-305 (2005) (emphasizing scientific concern regarding appreci-
ation of persistent organic pollutants); Arnold Schecter et al., Polybrominated Diphe-
nyl Ether Flame Retardants in the US. Population: Current Levels, Temporal Trends, and
Comparison with Dioxins, Dibenzofurans, and Polychlorinated Biphenyls, 47 J. OccuPA-
TIONAL & EIvrL. MED. 199, 200 (Mar. 2005) (discussing scientific concern that
PBDEs are only now being appropriately appreciated and comparing them with
other persistent organic pollutants).
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PBDEs are a class of flame retardants that since the 1960s95
have been "extensively used in a variety of consumer products such
as textiles, carpets, polyurethane foams, electronic cables, television
sets and computers."96 Some chemical compounds can be chemi-
cally bound in polymers so that it is difficult for them to escape
from the products and enter the environment; this is not the case
with PBDEs. They "are not fixed in the polymer product through
chemical binding, and can thus leak into the environment."97
Moreover, they have a number of chemical and biologically active
properties that are quite similar to other compounds known to
cause human developmental effects, and there is good reason to
believe that they will pose similar problems in humans once they
are well studied. Any such problems have not shown up to date,
either because they have not been studied in humans sufficiently
long enough, have not had a sufficiently long period to manifest
their adverse effects, or the adverse effects are sufficiently subtle
that they have not been detected with the crude tools of
epidemiology.
PBDEs are part of a general class of long-lived organic com-
pounds, which includes polychlorinated biphenyls (PCBs), orga-
nochlorine pesticides, and dioxins that tend to "remain in the
environment for a long period of time due to their high persis-
tence, and bioaccumulate in the food web."98 Many of these sub-
stances accumulate in animal and human tissues, especially body
fat. More specifically, they belong to a family "of pollutants called
polyhalogenated aromatic hydrocarbon [compounds, that include]
dioxins, polychlorinated dibenzofurans (PCDF), polychlorinated
diphenyl ethers, DDT, and polybrominated diphenyl ethers
(PBDEs) . . . ."9 Many members of this class are known to cause
developmental problems. PBDEs are specifically quite similar
chemically to PCBs, which have been extensively studied in both
animals and humans. There is substantial research showing that
PCBs cause developmental effects in both animals and humans.100
95. Hooper & McDonald, supra note 94, at 388 (stating use of PBDEs began
in 1960s).
96. Lucio G. Costa & Gennaro Giordano, Developmental Neurotoxicity of
Polybrominated Dipheny Ether (PBDE) lame Retardants, 28 NEURoToxICOLOGY 1047,
1048 (2007) (noting various products where PBDEs can be found).
97. Id. (suggesting reason why PBDEs are exceedingly dangerous).
98. Kodavanti, supra note 94, at 274 (explaining why PBDEs remain in envi-
ronment for extended period of time).
99. See id. (discussing chemical properties of PBDEs).
100. Id. at 276 (illustrating exposure and effect of PCBs on humans and vari-
ous other mammals).
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PBDEs are of "concern as a result of their association with endo-
crine disruption, reproductive and developmental toxicity, includ-
ing neurotoxicity, and cancer. ... "101
Animal studies of PBDEs alone provide reasons to believe that
there will be adverse neurotoxic effects in humans, since animal
models are routinely utilized to predict adverse effects in
humans.10 2
(1) Animal studies, carried out with different PBDEs, have
indicated that pre-and postnatal exposures to PBDEs may
cause long-lasting behavioral alterations, particularly in
the domains of motor activity and cognitive behavior.
101. Arnold Schecter et al., Polybrominated Diphenyl Ether Flame Retardants in the
U.S. Population: Current Levels, Temporal Trends, and Comparison with Dioxins,
Dibenzofurans, and Polychlorianted Biphenyls, 47J. OCCUPATIONAL & ENVTL. MED. 199,
200 (2005) (explaining why PBDEs are such great concern). See generally L. Birn-
baum & D. Staskal, Brominated Flame Retardants: Cause for Concern?, 112 ENVrL.
HEALTH PERSP. 9, 9-17 (2003); S. Hallgren & P. Darnerud, Effects of Polybrominated
Diphenyl Ethers (PBDEs), Polychlorinated Biphenyls (PCBs) and Chlorinated Paraffins
(CPs) on Thyroid Hormone Levels and Enzyme Activities in Rats, 35 ORGANOHALOGEN
COMPD. 391, 391-94 (1998); S. Hallgren & P. Darnerud, Polybrominated Diphenyl
Ethers (PBDEs), Polychlorinated Biphenys (PCBs) and Chlorinated Paraffins (CPs) in Rats
- Testing Interactions and Mechanisms for Thyroid Hormone Effect, 177 TOXICOLOGY, 227,
227-43 (2002); M. Gillner & E. Jakobsson, Structure-affinity Relationships for Thyroid
and Dioxin Receptor Binding of Halogenated Naphthalenes and Diphenylethers, 29 ORGA-
NOHALOGEN COMPD. 220, 220-21 (1996); I. Meerts et al., In Vitro Estrogenicity of
Polybrominated Diphenyl Ethers, Hydroxylated PDBEs, and Polybrominated Bisphenol A
Compounds, 109 ENVTL. HEALTH PERSP. 399, 399-407 (2001); I. Meerts et al., Placen-
tal Transfer of a Hydroxylated Polychlorinated Biphenyl and Effects on Fetal and Maternal
Thyroid Hormone Homeostasis in the Rat, 68 ToxIcoL Sci. 361, 361-71 (2002); D.
Morse et al., Interference of Polybrominated Biphenyls in Hepatic and Brain Thyroid Hor-
mone Metabolism in Fetal and Neonatal Rats, 22 ToxicoL APPL PHARMACOL 27, 27-33
(1993); I. Branchi et al., Effects of Perinatal Exposure to a Polybrominated Diphenyl Ether
(PBDE 99) on Mouse Neurobehavioural Development, 23 NEUROTOXICOLOGY 375, 375-84
(2002); P. Eriksson et al., A Brominated Flame Retardent, 2,2, 4,4"5-pentabromodiphenyl
Ether: Uptake, Retention, and Induction of Neurobehavioral Alterations in Mice During a
Critical Phase of Neonatal Brain Development, 67 ToxjCOL ScI. 98, 98-103 (2002); H.
Viberg et al., Neonatal Exposure to the Brominated Flame Retardent, 2,2"4,4,5-
pentabromodiphenyl Ether, Decrease Cholinergic Nicotinic Receptors in Hippocampus and
Affects Spontaneous Behavior in the Adult Mouse, 17 ENVIRON ToxICOL PHARMACOL. 61,
61-65 (2004); Envtl. Prot. Agency, 2,2',3,3',4,4',5,5',6,6' - Decabromodiphenyl
ether (BDE-209) (CASRN 1163-19-5), http://www.epa.gov/iris/subst/0035.htm#
reforal.
102. SeeJOHN M. ROGERS & ROBERTJ. KAVLOCK, DEVELOPMENTAL TOXICOLOGY,
CASARETT AND DOULL'S ToxICOLOGY (Curtis Klaassen ed., Pergamon Press, 6th ed.
2001) (discussing use of animal studies as close correlation for effects on humans).
"There have been several extensive reviews of the similarity of responses of labora-
tory animals and humans for developmental toxicants. In general, these studies
support the assumption that results from laboratory tests are predictive of poten-
tial human effects." Id. at 374. See generally Lucio G. Costa & Gennaro Giordano,
Developmental Neurotoxicity of Polybrominated Dipheny Ether (PBDE) Flame Retardants, 28
NEUROToxicoLOG 1047, 1061 (2007) (discussing further use of animal studies as
close correlation for effects on humans).
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Neurochemical changes have also been found following
developmental exposure to PBDEs. (2) PBDEs affect thy-
roid hormone homeostasis, which may result in develop-
mental neurotoxicity. (3) There is indication that young
animals may have reduced ability to excrete PBDEs, and
pups have higher tissue (including brain) concentrations
than the dams. (4) PBDEs are excreted in milk, and rela-
tively high concentrations are found in North America.
(5) Dust has been found to be a major source of exposure.
(6) Infants and toddlers have the highest body burden of
PBDEs, due to exposure via maternal milk and house
dust.103
The known structural similarities of PBDEs to PCBs and the
known similarity of PCBs' adverse effects in animals and humans,
together with known similarities between adverse effects of PCBs
and PBDEs in animals also predict adverse effects of PBDEs in
humans.10 4 "There is sufficient evidence that PCBs can cause neu-
rotoxicity in humans.., and it is believed that in utero exposure is
more important than lactational exposure in causing the neuro-
toxic effects."' 0 5 This evidence includes both accidental high dos-
age exposures in Japan and other events revealed in several
epidemiological studies. 10 6 PCBs and related compounds can cause
neurotoxicity in rats, mice, and monkeys.' 0 7 These include behav-
ioral changes and learning deficits resulting from both adult and
perinatal exposure. 0 8 Some of these effects resemble Attention
Deficit Hyperactivity Disorder. Exposure can also decrease cogni-
tive function in rats, primates and mice, impaired visual discrimina-
tion, altered spatial perception function, as well as deficits in
learning and memory. 0 9 Animal studies of PBDEs reveal similar
103. Costa & Giordano, supra note 96, at 1051 (quoting various findings from
animal studies with regards to PBDEs).
104. Hooper & McDonald, supra note 94, at 1051 (discussing known similari-
ties between PBDEs and PCBs).
105. See Kodavanti, supra note 94, at 275 (noting there is sufficient evidence
that PCBs have been shown to cause neurotoxicity in humans).
106. Id. at 275-77 (describing effects of PCB exposure).
107. Id. at 276 (illustrating exposure and effect of PCBs on humans and vari-
ous other mammals).
108. Id. at 277 (showing children of exposed women could be hypoactive or
hyperactive with varying degrees of behavioral problems).
109. Id. at 278 (describing both motor and cognitive effects of exposure).
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neurotoxic effects in animals. Exposure of animals to PCBs and
PBDEs produce similar neurotoxic outcomes.' 0
There appears to be a similar mechanism at work with both
PCBs and PBDEs. In general, the physical and chemical properties
of molecules affects their toxicity. I' In PCBs the shape of the mole-
cule affects its toxicity: so-called coplanar congeners (lying in the
same geometric plane) tend not to be active in disrupting intracel-
lular signaling, whereas non-coplanar congeners (not lying in the
same plane) tend to disrupt this signaling. Congeners are related
chemical substances with different numbers of key molecules at-
tached. Intracellular signals are "essential not only for the function
of the nervous system, but also play a key role in nervous system
development. Any interference with these processes would have
the potential for profound effects on the function of neuron [s] as
well as their development."'1 12 There are also reasons to believe
that PCBs produce their toxic effects by disrupting intracellular sig-
naling because of effects on learning and memory seen in human
epidemiological studies and effects at the molecular level. 113 The
important point is that PBDEs' non-coplanar structure is so similar
to PCBs non-coplanar structure that they will be active in disrupting
intracellular signaling as PCBs are.
PCBs and PBDEs have been shown [to] exert
neurobehavioral effects and cause changes in intracellular
signaling pathways in neuronal cells at equimolar doses/
concentrations suggesting a common mode of action for
these chemicals. Considering the structural similarities of
PBDEs and PCBs and the known health effects of PCBs in
110. See Kodavanti, supra note 94, at 297-98 (describing potential application
of PCB data to PBDEs).
111. INST. OF MED. AND NAT'L RESEARCH COUNCIL, COMM. ON THE FRAMEWORK
FOR EVALUATING THE SAFETY OF DIETARY SUPPLEMENTS, DIETARY SUPPLEMENTS: A
FRAMEWORK FOR EVALUATING SAFETY 205-06 (Nat'l Acads. Press 2005) (discussing
structure of toxic compounds). "The physical-chemical properties and biological
effects of a substance are derived from its chemical structure. If the chemical
structure of dietary supplement is known, but addition insight into the biological
activity is needed, then it is scientifically appropriate to consider the information
about the biological activity of structurally related substances. It is assumed that
the biological effects of chemicals, including toxic effect, are implicit in their mo-
lecular structures .... " Id. at 205-06.
112. See Kodavanti, supra note 94, at 281 (detailing significance of intracellu-
lar signaling). See generally S. Murphy et al., Phorbol Ester Stimulates Proliferation of
Astrocytes in Primary Cultures, 428 BRIN REs. 133, 133-35 (1987); P. R. Girard &J. F.
Kuo, Protein Kinase C and its 80-kilodalton Substrate Protein in Neuroblastoma Cell
Neurite Outgrowth, 54J. NEUROCHEM 300, 300-06 (1990).
113. See Kodavanti, supra note 94, at 281-83 (noting PCB's effects on intracel-
lular signaling).
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humans, these two groups of chemicals (may be other
structurally related chemicals) could conceivably work
through the same mechanism(s), to cause developmental
neurotoxicity. 1 1 4
The dose at which the adverse effects of PBDEs in animals oc-
curs is nearly equal on a per body weight basis to concentrations of
PBDEs in human tissues and bodies. In animals, the adverse effects
of PBDEs are seen "at exposure levels relevant to humans, at least in
North America." 15 Concentrations of PBDEs in individuals' bodies
are one to two orders of magnitude higher in the United States
than in Europe and the highest in the world. 116 In addition,
whereas the half-life of PBDEs in rodents "is in the order of several
days or months, the terminal total body half-lives in humans have
been estimated to be much longer, in the order of years . . ." for
some congeners and months for others.' 17 The longer a substance
remains in a mammalian body, the more time it has to inflict mo-
lecular damage that can lead to more serious organism damage. In
humans, the concentrations of PBDEs on a per body weight basis
seem to be highest in infants, next highest in children one to five
years of age, next highest in children six to eleven years of age, next
in children twelve to nineteen years old, and lowest (but still of con-
cern) in adults.118
Finally, it is important to recall that individuals are not merely
exposed to one substance at a time, nor are their bodies contami-
nated by one substance at a time. Researchers have found that
some low doses of PCBs alone or PBDEs alone do not show adverse
effects in rodents, but "co-exposure [of] the same low doses ...
produced significant behavioral alterations."' 19 Individuals' bodies
are also contaminated with "other developmental neurotoxicants
(e.g. lead, methylmercury, perchlorate, dioxins, etc.)," which could
114. Id. at 298 (recognizing similarity in PCBs and PBDEs). See generally P.
Eriksson et al., Brominated Flame Retardents: A Novel Class of Developmental Neurotoxi-
cants in Our Environment?, 109 ENVTL. HEALTH PERSP. 903, 903-08 (2001).
115. Costa & Giordano, supra note 96, at 1061 (describing need for reliance
on animal data for PBDEs).
116. Id. at 1049 (detailing sources for alarmingly high PBDE levels in humans
in North America).
117. Id. at 1061 (recognizing longer half-life of PBDEs in humans). The half-
life of substance in a mammalian body is the amount of time it takes for one-half of
the substance to be eliminated from the body.
118. Id. at 1050 (listing estimated exposure to PBDEs across different age
groups).
119. Id. at 1062 (illustrating potential synergistic effect of PCBs and PBDEs
and other neurotoxicants).
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have additive or synergistic effects, enhancing the adverse effects. 120
Since many of these compounds have long half-lives, they remain in
human bodies for substantial periods of time interacting with one
another.
There are some gaps in the PBDE-neurotoxicity picture, but
these are largely because of the absence of human studies. The
problem with gaps in the evidence is that they introduce some un-
certainty about conclusions and they provide an opportunity for ad-
versaries to argue that substances may not cause health problems in
humans as they do in many other biological systems. They open
the possibility of some scientific doubt that can be exploited to ar-
gue that the substances are less worrisome than the bulk of scien-
tific data supports. The question for the remainder of this Article is
whether the post-market legal structure governing most substances
(including PBDEs) is sufficiently protective for fetuses and develop-
ing children. Existing evidence concerning PBDEs and other sub-
stances reviewed in this Section suggests that they are not. It would
be a poor bet to rely on post-market laws to protect our children.
The chemical invasion revealed by the CDC biomonitoring and the
results of scientific research showing that chemical invaders can
enter, disrupt, and potentially cause adverse effects during the de-
velopmental process with possible further lifetime consequences
suggests that we should reconsider laws and legal structures for con-
trolling toxicants. The examples of PBDEs only reinforce this
concern.
IV. EXISTING HARM-BASED OR RISK OF HARM-BASED REGULATION
OF TOXICANTS
A. Regulatory Law
Current regulation of toxicants under administrative law is in
effect harm-based, or risk-of-harm based. In addition, to the extent
that tort or personal injury law serves to regulate exposures to toxi-
cants, except for some marginal causes of action, it is explicitly
harm-based. Moreover, to the extent that our laws are harm-based
or risk-of-of-harm based, it is arguable that existing laws do not
work or work well enough to protect our children.
Regulatory or administrative laws governing environmental
chemicals seek to prevent harms from exposures occurring in the
first place. They try to accomplish this aim through pre-market no-
120. Costa & Giordano, supra note 96, at 1062 (recognizing potential expo-
sure to other neurotoxicants).
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tification laws, pre-market testing and approval laws, and several va-
rieties of post-market laws.
1. Pre-Market Screening Laws
Some laws require manufacturers to notify the EPA that they
propose to manufacture new chemicals or use existing chemicals
for substantial new uses. Manufacturers must provide the EPA with
what they know about the products proposed for manufacture.
The Toxic Substances Control Act (TSCA) authorizes the agency to
review these products as they enter the market. 121 The EPA is then
given ninety days to review each substance for any toxicity proper-
ties, with the possibility of time extensions for further review or to
permit the EPA to request more data.1 22 There is, however, no le-
gally required amount of information a manufacturer must submit
to the agency and no minimal testing data; companies need only
report what they know about the product. Typically this includes
some chemical and physical properties as well as the chemical struc-
ture and some biological activity data about it. If the EPA identifies
some feature of concern about a substance, typically a chemical
structure that resembles other toxicants, under the TSCA new sub-
stances provisions it can require other data about or testing of the
product to try to determine whether it poses risks or harm to
humans or the environment. 123
In 1983, the Office of Technology Assessment found that about
one-half of the substances submitted for review contained no toxicity
information and "only 17 percent of [the chemicals proposed for
manufacture had] any test information about the likelihood of the
substance's causing cancer, birth defects or mutations-three bio-
logical effects that were singled out for special concern in
TSCA.' ' 124 In 1987, when revisiting the pre-market screening provi-
sions of TSCA, the Office of Technology Assessment reported that
121. Toxic Substances Control Act (TSCA), 15 U.S.C. §§ 2601-2692 (2006)
(providing text of Act).
122. U.S. Congress, Office of Technology Assessment, Identifying and Regulat-
ing Carcinogens, OTA-BP-FI-42, 216-17 (Washington, D.C.: U.S. Government Print-
ing Office, Nov. 1987) (stating EPA's obligations under Toxic Substances Control
Act).
123. Id. at 127 (discussing TSCA regulations with regard to environmentally
hazardous chemicals).
124. Id. (quoting U.S. Congress, Office of Technology Assessment, The Infor-
mation Content of Premanufacture Notices, OTA (Washington, D.C.: U.S. Government
Printing Office, 1983) (noting short-term tests on PMNs).
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"most PMNs [Premanufacture Notifications] do not contain any
toxicity test information .... ,,125
2. Pre-Market Testing and Approval Laws
Some laws, including laws under the authority of the FDA or
the EPA, are authorized to review substances, such as drugs and
new food additives, under the FDA, or pesticides, under the EPA,
before they enter commerce and substantial human exposure occurs.
Such laws impose testing requirements for the substances, agency
review of the test data, some level of demonstrated safety (or mini-
mization of risks), and explicit agency approval before the products
are permitted to enter commerce. The language of many of these
statutes is explicitly that of avoiding risk of harm. According to a
1984 National Research Council (NRC) report, however, the sub-
stances governed by pre-market testing and approval laws cover
only a relatively small portion of the chemical universe that was in
existence at that time, at most about twenty percent and it could be
less than ten percent. 126 Even though the goal is to detect toxicants
before they enter commerce and there is substantial pre-market
testing, unless the laws authorize tests specifically for developmen-
tal toxicants, they will not be detected. Moreover, the pre-market
testing provisions do not work perfectly, so some toxic effects will
be missed despite the best and most conscientious efforts. When
this occurs, if manufacturers and agencies have been vigilant, this
may be the best situation for which citizens can reasonably ask. The
regulatory law of the United States has not achieved this goal for
the vast majority of substances.
3. Post-market Laws
Finally, a large majority of substances (approximately eighty
percent, and possibly as high as ninety percent) are regulated
under post-market laws. Post-market laws permit products to enter
commerce without any legally required testing. Since 1980, sub-
stances that would otherwise only be subject to post-market laws
have been subject to the TSCA pre-market screening provisions de-
scribed above. Under this provision the EPA is provided whatever
data manufacturers know about the substance, but there is no le-
gally prescribed testing or minimally required data. Agencies, such
125. Id. (stating PMNs do not contain toxicity test information).
126. NAT'L RESEARCH COUNCIL, ToxicrY TESTING: STRATEGIES TO DETERMINE
NEEDS AND PRIORITIES 11 (Nat'l Acad. Press 1984) (reporting statistics on health
hazard information).
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as the Occupational Safety and Health Administration (OSHA), the
Consumer Product Safety Commission (CPSC), the FDA, and the
EPA must then review substances under laws that require them to
identify risks of harm from the products after they are in commerce and
take steps to reduce or eliminate any risks or harms from them.
Under virtually all post-market laws regulatory agencies bear
the burden of proof to show risks of harm, actual harm or at least
the toxicity of substances before any legal regulation can occur.
127
In addition, substantive legal provisions central to some post-mar-
ket laws exacerbate the agencies' difficulties. Scientific documenta-
tion of risks or harms creates further and high hurdles.
Some laws require agencies to identify toxicants and then au-
thorize the use of technology to reduce exposures to the lowest
achievable level or perhaps to force the development of improved
technology to ensure lower exposures.12 8 Other "warning laws" re-
quire the identification of toxicants and might require those caus-
ing the exposure to warn the public about the risks. 129 Technology-
forcing and warning laws simplify some government tasks depend-
ing upon the statute. In general, they only require agencies to iden-
tify toxicants and then utilize the best available technology to
reduce exposures or to post warnings, respectively. 130 While these
laws appear to be comparatively simple and straightforward, there
can be a number of disputes concerning to which industries the law
applies, the technologies manufacturers are required to adopt and
the extent to which technologies should reduce exposures to toxi-
cants, all taking considerable time. 3 1
127. California's Proposition 65 does not follow this pattern, since once the
state has listed a substance as a reproductive or carcinogenic toxicant, the burden
of proof falls on firms that expose the public to the toxicant. See Office of Envtl.
Health Hazard Assessment, Proposition 65, http://www.oehha.org/prop65.html
(providing additional information about Proposition 65).
128. U.S. Congress, Office of Technology Assessment, Identifying and Regulat-
ing Carcinogens, OTA-BP-FI-42, 199-200 (Washington, D.C.: U.S. Government Print-
ing Office, Nov. 1987) (detailing regulatory carcinogen laws).
129. California's Proposition 65 is one example of such a law. See Safe Drink-
ing Water and Enforcement Act of 1986, CAL. HEALTH & SAFETY CODE § 25249.5
(1989) (requiring public warning of risks associated with hazardous chemicals).
130. See U.S. Congress, Office of Technology Assessment, Identifying and Regu-
lating Carcinogens, OTA-BP-FI-42, 127 (Washington, D.C.: U.S. Government Print-
ing Office, Nov. 1987) (discussing how few toxicants submitted as part of PMNs
have any testing); see also Carl F. Cranor, Information Generation and Use Under Pro-
position 65: A Model for Other Post-market Laws, 83 IND. L. REV. (forthcoming 2008)
(stating California's Proposition 65 requires firms to post clear and reasonable
warnings).
131. See Bruce A. Ackerman & Richard B. Stewart, Comment: Reforming Environ-
mental Law, 37 STAN. L. REv. 1333, 1333-365 (1985) (discussing criticisms of tech-
nology forcing laws).
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Other laws require the setting of "ambient-exposure" levels to
protect citizens. Government agencies bear the burden to prove
that substances pose risks and the burden to determine exposure
levels in the relevant environment so that statutorily mandated pro-
tection will be met. Such laws are especially onerous from the point
of view of the regulator. When agencies are authorized to act
under ambient-exposure laws, they must not only identify a sub-
stance as toxic to humans or the environment, or as posing risks
thereto, but specify the approximate amount of exposure that poses
a risk or harm, and then estimate whether there are exposure levels
in the environment that necessitate regulation. Substantive legal
provisions might require regulations to prevent "unreasonable risks
of harm to health," to prevent human health risks "with an ade-
quate (or ample) margin of safety," to prevent exposure to sub-
stances which cause "cancer in humans or animals," or to "prevent
material impairment of health or functional capacity."'1 2 Ambient
exposure laws typically require all four stages of risk assessment:
hazard identification; potency assessment; exposure assessment;
and an overall risk characterization as part of the regulatory pro-
cess. 133 Carrying out these tasks is quite science-intensive and time-
consuming. Such laws impose a burden on the agency to provide
evidence of risk or harm sufficient to justify regulation and to avoid
being overturned on appellate review. These legal structures conse-
quently invite manufacturers who are subject to regulation to raise
skeptical concerns about the evidence, to delay, to be slow in pro-
ducing any needed data about their products, to argue that there is
insufficient information to justify the regulation, or to argue that
there is too much uncertainty to permit an agency to issue a regula-
tion at the current time. All this tends to delay regulatory action, to
increase the implicit scientific and legal standards of proof that
must be satisfied, to keep products in commerce longer, and to
leave the public exposed to risks of harm longer while an agency
deliberates about the issues. 134 Appellate review has been increas-
132. U.S. Congress, Office of Technology Assessment, Identifying and Regulat-
ing Carcinogens, OTA-BP-FI-42, 122, 127-28, 200-01, 215 (Washington, D.C.: U.S.
Government Printing Office, Nov. 1987) (discussing potential legal requirements).
133. NAT'L RESEARCH COUNCIL, RISK ASSESSMENT IN THE FEDERAL GOVERNMENT
3 (Nat'l Acads. Press 1983) (delineating four typical stages of risk assessment cov-
ered by ambient exposure laws).
134. In addition, there appears to be poor monitoring of products once they
are in the market to alert the company or the relevant agency of risks or harms
that might be caused by their products.
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ingly intrusive since the Supreme Court's benzene decision 35 in
1980 that affected not only the Occupational Safety and Health Ad-
ministration (whose regulation was at issue) but other regulatory
agencies as well by producing a "chilling effect" on their
activities. '"6
Consumer products, subject to national regulation, including
plastic consumer products as well as lead in toys or jewelry, appear
to be poorly regulated by the Consumer Product Safety Act and the
Federal Hazardous Substances Act. 137 In 1985, the Consumer Prod-
uct Safety Commission was quite small and had only a few toxicolo-
gists responsible for carcinogens. It is now even smaller and has
fewer scientists to test products. Other agencies may not be so evis-
cerated, but Congressional funding for inspections and enforce-
ment has tended to be substantially curtailed.
In theory, post-market laws authorize or encourage the use of
surrogate means to identify risks before they materialize into actual
human health and environmental harm. For example, the laws en-
courage the use of animal studies and other non-human evidence.
In the early periods of regulatory activity, beginning in the 1970s,
typically the risk information was based upon animal studies seek-
ing to identify risks in mammalian models before substances caused
harm to humans.' 38 Despite the early emphasis on surrogates to
identify risks to humans, there is constant pressure from affected
industries to challenge the scientific value of animal and other
kinds of evidence, as well as pressure to which agencies may acqui-
esce to support their regulations by epidemiological evidence of
human harm. For example, a National Academy of Sciences (NAS)
committee recommends "the most stringent criteria and requires
epidemiologic evidence for drawing any positive conclusions about
potential carcinogenicity; animal evidence and other test informa-
135. See Indus. Union Dept., AFL-CIO v. Am. Petroleum Inst., 448 U.S. 607 (1980)
(providing opinion regarding issue of exposure to benzene).
136. Carl F. Cranor, The Regulatoy Context for Environmental and Workplace
Health Protections: Recent Developments, in THE BLACKWELL GUIDE TO BUSINESS ETHICS
77-101 (Norman Bowie ed., Blackwell Publishers 2002) (identifying chilling effect
stemming from benzene decision); THOMAS 0. McGARTY & SIGNEY A. SHAPIRO,
WORKERS AT RISK: THE FAILED PROMISE OF THE OCCUPATIONAL SAFETY AND HEALTH
ADMINISTRATION 257-58 (Greenwood Publ'g Group 1993) (describing adverse con-
sequences to agencies of overzealous judicial review of agency actions).
137. SeeConsumer Product Safety Act, 15 U.S.C. §§ 2051-2084 (2006) (provid-
ing text of Act); Federal Hazardous Substances Act, 15 U.S.C. §§ 1261-1278 (2006)
(providing text of Act).
138. U.S. Congress, Office of Technology Assessment, Identifying and Regulat-
ing Carcinogens, OTA-BP-FI-42, 122, 26, 32-33, 45-52 (Washington, D.C.: U.S. Gov-
ernment Printing Office, Nov. 1987) (describing cancer risk assessment policies).
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tion are used only to confirm cancer causation once epidemiologi-
cal associations have been demonstrated."' 139
Fortunately, for public health protections, more recent NAS
committees have disagreed with this view, recognizing that animal
and other kinds of evidence can legitimately support regulatory ac-
tions. 140 To the extent that agencies are under pressure and regu-
late on the basis of human harm, risk-based statutes or statutes that
explicitly anticipated the use of surrogates as a basis for regulation
become human harm-based laws and lose any protective effects re-
sulting from early detection of toxicants. In other words, humans
must suffer harm before toxicants can be justifiably regulated to
prevent harm to others.
This concern is heightened if one understands the commonly
used tool for discovering evidence of human harm - human epide-
miological studies. Epidemiological studies are statistics-based stud-
ies comparing either persons exposed to a toxicant with persons
not so exposed (a cohort study), or comparing persons with disease
to persons without (a case-control study). In each instance, the aim
is to isolate and identify what diseases the exposures cause. 141 Epi-
demiological studies are notoriously insensitive, however. As the
joke goes, a catastrophe is something that even an epidemiological
study can detect. Epidemiological studies can detect more com-
mon diseases and identify gross adverse effects with comparative
ease where exposures are reasonably precise. They will, however,
have much greater difficulty detecting diseases that have long la-
tency periods, that are comparatively rare, that have new causes for
common conditions (difficulty distinguishing the noise of a com-
mon disease from a new causal effect), that lack signature effects, or
139. COMM. ON ToxiciTy TESTING AND ASSESSMENT OF ENVrL. AGENTS ET AL.,
ToxicITY TESTING FOR ASSESSMENT OF ENVIRONMENTAL AGENTS: INTERIM REPORT
134-38 (Nat'l Acads. Press 2006) (requiring epidemiologic evidence of human
harm for positive conclusions on carcinogenicity and assigning animal evidence to
merely supporting role).
140. See INST. OF MED., COMM. ON EVALUATION OF THE PRESUMPTIVE DISABILITY
DECISION-MAKING PROCESS FOR VETERANS, IMPROVING THE PRESUMPTIVE DISABILITY
DECISION-MAKING PROCESS FOR VETERANS 139-60 (J. M. Samet & C. C. Bodurow
eds., Nat'l Acads. Press 2000) (discussing the need to combine diverse types of
evidence in making judgment about whether exposure causes health concerns); see
also NAT'L RESEARCH COUNCIL, TOXICITY TESTING IN THE TWENTY-FIRST CENTURY- A
VISION AND A STRATEGY 21-38 (Nat'l Acads. Press 2007) (discussing risk
assessment).
141. See CARL F. CRANOR, Toxic TORTS: SCIENCE, LAW AND THE POSSIBILITY OF
JUSTICE 96-97 (Cambridge Univ. Press, 2006) (providing description of different
types of epidemiological studies); KENNETH J. ROTHMAN & SANDER GREENLAND,
MODERN EPIDEMIOLOGY 73-74 (Lippincott Williams & Wilkins 2d ed. 1998) (discuss-
ing different types of epidemiological studies).
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that have subtle adverse effects (which are likely to be typical of
many developmental effects). 142 Where exposures are difficult to
determine, scientific conclusions become much more tentative.
Adverse effects triggered during development could take years, if
not decades, to be identified by epidemiological studies. Scientists
could identify obvious adverse outcomes, such as shortened limbs,
but would have much greater difficulty tracing the causes of short-
ened attention spans or reduced IQ from lead exposures. 43
Consequently, under post-market statutes, substances enter
commerce without any legally mandated testing and no indepen-
dent certification of some degree of safety. They remain in com-
merce providing financial benefits to manufacturers. If they cause
harm, this harm continues until a regulatory agency presents a suffi-
ciently strong scientific and legal case proving harm or risk of harm
based upon animal and human evidence. If human evidence is in-
sisted upon before there is regulation, these difficulties will be sub-
stantially exacerbated. For developmental toxicants that are subtle
and that take years to manifest adverse effects, many cohorts of chil-
dren will be subject to adverse outcomes before the risks are identi-
fied and eliminated. Under post-market laws the American
citizenry are, in effect, human guinea pigs for the commercial cre-
ations of American industry. Our children are even more likely to
be experimented upon and the harms may be more difficult to de-
tect. This is not a health-protective approach toward our children.
Even risk-based laws utilizing non-human evidence, however,
may not function well. Long-term animal studies commissioned by
a government agency can easily take seven years to authorize, con-
duct, and analyze in order to produce usable results for regula-
tion.1 44  If manufacturers do not test products before
142. See CRINoR, supra note 141, at 225-27 (noting strengths and weaknesses
of epidemiological studies); see also Rail et al., Alternatives to Using Human Experience,
355-85; Huff & Rall, Relevance to Humans, 433; ELAINE FAUSTMAN & GILBERT S.
OMENN, RISK ASSESSMENT, CASARETT AND DOULL'S ToxICOLOGY: THE BASIC SCIENCE
OF POISONS 86 (Curtis D. Klaassen, ed., McGraw-Hill 6th ed. 2001); S. R. Silver et
al., Effect of Follow-Up Time on Risk Estimates: Longitudinal Examination of the Relative
Risks of Leukemia and Multiple Myeloma in Rubber Hydrochloride Cohort, 42 AM. J. IN-
DUS. MED. 481, 481-89 (2002).
143. Grandjean & Landrigan, supra note 25, at 2167-178 (discussing difficul-
ties in determining cause of some adverse effects).
144. CARL F. CRANOR, REGULATING TOXIC SUBSTANCES: A PHILOSOPHY OF SCI-
ENCE AND THE LAw 27 (Oxford Univ. Press 1993) (stating difficulty of animal stud-
ies commissioned by government agency); see also U.S. Congress, Office of
Technology Assessment, Identifying and Regulating Carcinogens, OTA-BP-FI-42, 17
(Washington, D.C.: U.S. Government Printing Office, Nov. 1987) (discussing time
line for animal studies). The Author and Karl Kronebusch of the Office of Tech-
nology Assessment also personally interviewed risks assessors at the U.S. EPA Air
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commercialization, and the products cause adverse developmental
effects in children, these affected children will continue to be born,
exposed to toxicants for a minimum of seven years (and probably
much longer). This could easily be the case with PBDEs. They
have been in commerce since the early 1970s without testing before
commercialization (despite similarities to PCBs), are in high con-
centrations in children's and adults' bodies, and now appear to pre-
sent quite serious risks to children and perhaps to adults. Post-
market laws do not prevent substantial exposures and any harm
they might cause. At some time in the future there might be
shorter-term tests that can accurately identify developmental toxi-
cants, but until then, agencies will need to rely on the testing tech-
nologies that are currently available, despite their shortcomings.
When pre-market or post-market laws fail to catch risks before harm
occurs to the public, the workforce, or the environment, tort or
personal injury law offers the possibility of correcting the mistakes
for particular individuals who seek redress. 145
B. Harm-Based Tort (Personal Injury) Law
Tort law seeks to set matters right for a victim, typically by pro-
viding post-injury compensation sufficient to restore the injured
person to the condition in which he or she would have been had
the injury not occurred in the first place. In addition, the effects of
general deterrence (the general threat of tort actions) or deterrence by
example (any deterrence resulting from successful legal actions
against others for harmful behavior or products) can include the
modification of risky behavior and products prior to any further
harm occurring. The extent of tort law deterrence is unclear, re-
flecting differing views in applicable literature.
Tort law addresses potential toxicants after the fact of an injury
to a plaintiff, and virtually all legal causes of action must show evi-
dence of some kind of harm. 146 In tort law, a plaintiff, the person
claiming injury from a toxic substance, typically must show that a
particular defendant's substance more likely than not can cause the
kind of injury from which the plaintiff suffers and more likely than
Toxics Program in Washington, D.C. at the U.S. EPA main office who reported
such long time-lines for testing April 1986.
145. See CRANOR, supra note 141, at 355-57 (putting tort laws in context with
pre-market laws). See generally KEETON, infra note 185.
146. There are a few causes of action that do not explicitly require a showing
of harm in order to justify a remedy, such as being at a increased risk of serious
disease, medical monitoring, or reasonable fear of serious disease, such as cancer.
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not caused plaintiffs injuries. 14 7 Thus, any "regulation" of toxi-
cants by tort law (e.g., reductions in exposures, product reformula-
tions or removal from the market) is post-market, harm-based, and
post-injury at least for those harmed. The extent of deterrence that
litigation, provides is not clear, since individual companies could
choose to respond quite differently to adverse legal decisions affect-
ing other companies. Although tort law should allow for non-
human scientific evidence of various kinds to show the potential
human toxicity of products since scientists typically rely upon such
evidence, there is even greater pressure by defendants and some
judges to have plaintiffs provide evidence of harm based upon
human studies. 148 To the extent that defense efforts are successful
or judges require such showings, before a plaintiff can "put matters
right" with a defendant whose products are believed to be harmful
to the plaintiff, other persons must have already been harmed.
149
Tort law need not make such demands, but it is in defendants' in-
terests to press for them and some judges require this before scien-
tific experts are permitted to testify.
15 0
147. See Donaldson v. Cent. Ill. Pub. Serv. Co., 767 N.E.2d 314 (2002) (show-
ing that not all jurisdictions insist on this rigid legal distinction).
148. See CRANOR, supra note 141, at 224 (emphasizing court's demand for
human data as necessary foundation for expert testimony); see also In re Agent
Orange Prod. Liab. Litig., 611 F. Supp. 1223, 1231 (E.D.N.Y. 1985); Lynch v. Mer-
rell-National Lab., Div. of Richardson-Merrell, Inc., 830 F.2d 1190 (1st Cir. 1987);
Brock v. Merrell Dow Pharm., Inc., 874 F.2d 307, 312 (5th Cir. 1989), cert. denied,
494 U.S. 1046 (1990); Richardson v. Richardson-Merrell, Inc., 857 F.2d 823, 825,
831 n.59 (D.C. Cir. 1988), cert. denied, 493 U.S. 882 (1989); Renaud v. Martin Mari-
etta Corp., 749 F. Supp. 1545 (D. Colo. 1990); Carroll v. Litton Sys., Inc., No. B-
C88-253, 1990 WL 312969, at *47 (W.D.N.C. Oct. 29, 1990); Thomas v. Hoffman-
La-Roche, Inc., 731 F. Supp. 224 (N.D. Miss. 1989), affd on other grounds, 949 F.2d
806 (5th Cir. 1992); Chambers v. Exxon Corp., 81 F. Supp. 2d 661 (M.D. La.
2000).
149. ToNY HONORk, THE MORALITY OF TORT LAW - QUESTIONS AND ANSWERS,
PHILOSOPHICAL FOUNDATIONS OF TORT LAW 79 (David G. Owen ed., Clarendon
Press 1995) (characterizing aims and rationales of tort law).
150. See CRANOR, supra note 141, at 237-38 (arguing against requirement in
tort law that other people must have suffered similar injuries); see also In re Agent
Orange Prod. Liab. Litig., 611 F. Supp. 1223, 1231 (E.D.N.Y. 1985); Lynch v. Merrell-
National Lab., Div. of Richardson-Merrell, Inc., 830 F.2d 1190 (1st Cir. 1987); Brock v.
Merrell Dow Pharm., Inc., 874 F.2d 307, 312 (5th Cir. 1989), cert. denied, 494 U.S.
1046 (1990); Richardson v. Richardson-Merrell, Inc., 857 F.2d 823, 825, 831 n.59 (D.C.
Cir. 1988), cert. denied, 493 U.S. 882 (1989); Renaud v. Martin Marietta Corp., 749 F.
Supp. 1545 (D. Colo. 1990); Carroll v. Litton Sys., Inc., No. B-C88-253, 1990 WL
312969, at *47 (W.D.N.C. Oct. 29, 1990); Thomas v. Hoffman-La-Roche, Inc., 731 F.
Supp. 224 (N.D. Miss. 1989), affd on other grounds, 949 F.2d 806 (5th Cir. 1992);
Chambers v. Exxon Corp., 81 F. Supp. 2d 661 (M.D. La. 2000).
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C. Ignorance of the Toxicity Properties of Products
The existing legal structure is not adequate to identify toxic
substances early and before commercialization, making it more dif-
ficult to prevent diseases and adverse effects of toxic substances es-
pecially for children. In 1984, when the NRC sought to determine
the current knowledge base regarding manufactured chemical sub-
stances in commerce, the results were disturbing. There were:
* 12,860 substances produced in volumes exceeding one
million pounds per year; 78 percent of which had no
toxicity information available, while eleven percent had
minimal toxicity information (but insufficient for a com-
plete risk assessment) [post-market];
* 13,911 chemicals produced in volumes of less than one
million pounds; 76 percent with no toxicity data, twelve
percent had minimal toxicity information) [post-
market];
* 21,752 chemicals production volume unknown; there
was no data on 82 percent and had minimal toxicity
data.
e 8,627 food additives, 46 percent had no toxicity data, 34
percent had some toxicity information (but below the
minimal level) and one percent had minimal toxicity in-
formation [some post-market];
* 1,815 drugs; twenty-five percent had no toxicity data, 36
percent had some toxicity data (but below the minimal
level) and three percent had minimal toxicity
information;
* 3,410 cosmetics; 56 percent had no toxicity data, eigh-
teen percent had some toxicity data (but below the min-
imal level) and ten percent had minimal toxicity
information [post-market];
* 3,350 pesticides; 36 percent had no toxicity data, twenty-
six percent had some toxicity data (but below the mini-
mal level) and two percent had minimal toxicity
information. 151
The vast majority of substancesare subject to post-market regu-
lation and the consequence has been substantial ignorance about their
151. See NAT'L RESEARCH COUNCIL, supra note 126, at 12 (providing statistics
on ability to conduct health-hazard assessment of various substances). The data
presented here comes from Toxicrrv TESTING, but the presentation and organiza-
tion are the Author's.
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toxicity. On average, as near as one can estimate for eighty to ninety
percent of substances subject to post-market laws, there is no toxicity
data for about seventy percent of them.
The ignorance of drugs, pesticides, and new food additives, all
chemicals subject to pre-market testing and approval laws, was not
as serious as the ignorance of substances regulated under post-mar-
ket statutes. Even the above statistic, however, is not especially im-
pressive given that pre-market testing is required for some food and
drug products because they had been grandfathered by federal reg-
ulation and were not subject to procedural testing laws. In the early
1990s, some members of the original NRC committee were asked to
consider updating the NRC report, but insufficient changes in the
data did not warrant an update. 152 In 1998, there remained sub-
stantial knowledge-gaps for about seventy-five percent of approxi-
mately three thousand substances produced in the highest volume
when the EPA entered into a voluntary agreement with producers
to close the knowledge-gaps. 153 Major chemical companies spon-
sored about 1,900 of about 2,800 substances for which there was
agreement to provide toxicity data, but about ten percent of the
substances eligible for sponsorship remain without sponsors. Two
and one-half years after the deadline for industry to submit final
datasets, about one-fifth have not provided initial submissions and
of those that have, one-third have not submitted final datasets.
1 54
Public release of the substances data from EPA has been delayed
eighteen months. 155
The 3,000 substances produced in the highest volume might
have been the most worrisome, but the United States Congress Of-
fice of Technology Assessment (OTA) found that there are an addi-
tional one thousand to twelve thousand substances for which
extensive toxicological information would be important but was not
152. Conversation with John C. Bailor & Eula Bingham, (2002) (reporting
discussion with NRC concerning possible update to NRC report).
153. Envtl. Prot. Agency et al., EPA, EDI, CMA Agree on Testing Program Target-
ing 2,800 Chemicals, 37 ENVrL. HEALTH LETrER 193, 193 (Oct. 1998) (detailing
agreement with Chemical Manufacturers Association for volunteering toxic prod-
ucts for testing purposes).
154. RICHARD DENNISON, PH.D., EN-VrL. DEF., HIGH HOPES, Low MARKS: A Fi-
NAL REPORT CARD ON THE HIGH PRODUCTION VOLUME CHEMICAL CHALLENGE 3 (July
2007), http://www.environmentaldefense.org/documents/6653_HighHopesLow
Marks.pdf (discussing final assessment for HPV Challenge, which was established
by EPA and negotiated with manufacturers of HPV chemicals).
155. Id. at 3 (discussing that data sets were delivered to EPA more than eigh-
teen months later than deadline for public release).
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available. 156 These results suggest that any risks resulting from the
products of a free enterprise system are beyond the understanding
and control of the legal institutions designed to protect the pub-
lic. 157 The post-market harm-based or risk-of-harm-based legal
structure is failing to produce toxicity data about the products sub-
ject to its jurisdiction so that adverse effects can be prevented.
There is evidence that the ignorance of the toxic properties of sub-
stances is not accidental. For example, Margaret Berger has
pointed out that a corporation subject to regulation or a tort action
did not test its product adequately initially, failed to im-
part information when potential problems emerged, and
did not undertake further research in response to adverse
information. It appears that the corporations took virtu-
ally no steps to determine or minimize the possibility of
harm until their hands were forced, usually by litigation.
Only after extensive and expensive discovery have docu-
ments and witnesses come to light that showed the corpo-
rations' awareness of potential problems.158
156. See OFFICE OF TECH. ASSESSMENT, CONGRESS OF THE U.S., OTA-BP-ENV-
166, SCREENING AND TESTING CHEMICALS IN COMMERCE 1 (1995) (explaining impor-
tance of additional toxicological information). There are "some 15,000 chemicals
that are produced in significant volumes, with approximately 3 - 4,000 produced in
excess of 1,000,000 lbs/year." Id. Subtracting that 3,000 produced in excess of 1
million pounds leaves up to 12,000 produced in "significant volumes" about which
there appears to be some concern. Id.
157. See POUL HARREMOES ET AL., LATE LESSONS FROM EARLY WARNINGS: THE
PRECAUTIONARY PRINCIPLE 1896-2000 11, 168-69 (Poul HarremoEs et al. eds., Euro-
pean Envtl. Agency 2001). There have also been high profile harms to health and the
environment done by DDT, chloroflurocarbons, PCBs, lead, mercury, cadmium,
nickel, benzene, asbestos, and other toxicants, as well as poor disposal practices.
There is little monitoring/surveying of the current state of the environment and public
health. There are some reporting requirements as part of the Food, Drug and Cos-
metic Act, (requiring reports on adverse drug and vaccine reactions) and as part of
the Toxic Substances Control Act and the Occupational Safety and Health Act
(requiring medical record-keeping and reporting of toxicity effects). There may
be a few other such requirements, but the efforts appear insufficient to provide a
systematic picture. Often, long-term effects are even less well-known than short-term
adverse effects. There appears to be little or no understanding of the life cycle of prod-
ucts. There also appears to be little sensitivity or response to credible warnings of serious
adverse effects. In LATE LESSONS FROM EARLY WARNINGS: THE PRECAUTIONARY PRINCI-
PLE 1896-2000, the European Environmental Agency notes that in the past there
have often been credible early warnings of adverse effects on human health or the
environment that went unheeded; there were no (or slow) legal or other social
responses. Finally, even once a problem has been identified, there are often slow
procedures to remove substances or reduce their risks. See id.
158. Margaret A. Berger, Eliminating General Causation: Notes Towards a New
Theory of Justice and Toxic Torts, 97 COLUM. L. REv. 2117, 2135 (1997) (emphasis
added) (discussing flaws in toxic tort litigation). Berger cites in particular studies
of Agent Orange, asbestos, Bendectin, breast implants, the Dalkon Shield,
thalidomide, tobacco, MER/29 (a cholesterol-reducing drug that caused cata-
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Berger's concern has been echoed by others.1 59
This, however, should not come as a surprise. The regulatory
and tort law structures provide implicit incentives for manufactur-
ers to refrain from testing their products. If they do conduct tests,
they may be tempted to design the tests so that they do not detect
adverse effects.' 60 Additionally, self-interested considerations may
prevent the full report of research findings, even when adverse ef-
fects are identified. Testing will only invite legal problems; tests
showing even minimal adverse effects will invite inquiries from reg-
ulatory agencies or suits by tort lawyers. There are examples of
these responses in the last thirty years, some within the last year. 161
Each year the National Toxicology Program authorizes only a
small number of animal tests on potentially cancerous sub-
stances.' 62 It is unclear the extent to which testing for other kinds
of toxicity is authorized. Post-market testing, assessment and follow
racts), alachlor, atrazine, formaldehyde, and perchloroethylene. See id.; see also
BARRY I. CASTLEMAN, REGULATIONS AFFECTING USE OF CARCINOGENS, CANCER CAUS-
INC CHEMICALS 78 (N. Irving Sax ed., Van Nostrand Reinhold 1981) (discussing
flaws in toxic tort litigation with respect to carcinogenic materials such as asbes-
tos); David E. Lilienfeld, The Silence: The Asbestos Industry and Early Occupational Can-
cer Research- A Case Study, 81 AM.J. PUB. HEALTH 791, 791-98 (1991) (discussing
flaws in toxic tort regulation with respect to asbestos); David Michaels, Waiting For
The Body Count: Corporate Decision Making and Bladder Cancer in the U.S. Dye Industry,
2 MED. ANTHROPOLOGY Q. 215, 215-27 (1988) (discussing flaws in toxic tort litiga-
tion in context of cancer causing dyes); Donald R. Mattison & John E. Craighead,
Reproductive System, in PATHOLOGY EVTL. & OCCUPATIONAL DISEASE 559-72 (John E.
Craighead ed., Mosby 1995) (discussing flaws in toxic tort litigation in American
occupational environment). In some instances, even responsible firms may also
fall prey to ambiguity and difficulty in interpreting data and scientific studies.
159. See e.g., Carl F. Cranor & David A. Eastmond, Scientific Ignorance and Relia-
ble Patterns of Evidence in Toxic Tort Causation: Is There a Need for Liability Reform?, 64
LAw & CONTEMP. PROBS. 5 (2001) (discussing fact that plaintiffs are placed in posi-
tion where they must expend large sums of money to prove they were exposed to
dangerous chemicals, when chemicals toxicity could have been studied and deter-
mined before public exposure).
160. See CRANOR, supra note 141, at 357 (discussing market incentives that
keep companies from fully investigating toxic effects of chemicals before they are
placed in stream of commerce); see alsoJohn C. Bailar, III, How to Distort the Scien-
tific Record Without Actually Lying: Truth, and the Arts of Science, 11 EUR. J. ONCOLOGY,
217, 218 (2006) (describing paths of manipulation that can be used to "lie with
statistics" and other techniques to distort toxicity of products).
161. Alex Berenson, Follow-Up Study on Vioxx Safety is Disputed, N. Y. TIMES, May
13, 2006, available at http://www.nytimes.com/2006/05/13/business/13merck.
html?n=top/Reference/Times%20Topics/Subjects/L/Liability%2OFor%2OProd-
ucts&pagewanted=all# (reporting that Merck interpretation of study showing pa-
tients who ceased taking Vioxx after one year were at no significant risk for heart
attacks was "narrowly correct, but misleading").
162. Conversation with Ronald Melnick, Senior Toxicologist and Director of
Special Programs, Environmental Toxicology Program, National Institute of Envi-
ronmental Health Services (Oct. 25, 2002) (explaining how few substances are
tested for toxicity each year on animals).
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up of suspect substances lags far behind the production of new sub-
stances. If federal or state agencies have not assessed the toxicity of
substances, it is unlikely that others have tested the substances or
that there is sufficient public information about the products.
There are numerous and substantial problems with post-mar-
ket laws. The public will be protected only if government agencies
act (or successful tort suits lead to the removal or reduction of the
cause of harm), but they must act in legally difficult circumstances.
The agency has the burden to change legal relationships. It must
meet that burden and withstand review by an appellate court, which
has become increasingly difficult in recent years. 163 New scientific
studies needed to support legal action take up to seven years for
animal studies, and possibly much longer for human studies to al-
low for the induction and latency periods of disease (e.g., much
longer for developmental effects that take time to manifest them-
selves, such as learning disabilities). 164 Human studies take much
longer for developmental effects, such as learning disabilities, to
manifest themselves. Regulated parties subject to administrative
proceedings often possess tests on products and exposure data, es-
pecially in occupational settings, allowing them to substantially af-
fect whether data are revealed and influence a regulatory outcome.
Moreover, legal action is delayed by claims that more evidence is
needed, that the science presented is not sufficiently sound, and
that conclusions must be asserted with greater certainty. 165 Further
research into scientific conclusions can delay regulation or court
decisions for years or sometimes decades. 166
163. Cranor, supra note 136, at 77-78 (discussing agency challenge of enforc-
ing and litigating post-market tort and toxicity laws). Moreover, regulatory action
has become increasingly data and evidence intensive as regulated industries in-
creasingly challenge legal action and their challenges are upheld by federal courts.
See id. This feature of the regulatory world means that because of the data inten-
sive nature of regulation, extensive documentation of the legal record, protective
regulations often take years or even decades before exposures are reduced to safe
or safer levels. See id.
164. KENNETH J. ROTHMAN & SANDER GREENLAND, Types of Epidemiologic
Studies, in MODERN EPIDEMIOLOGY 67, 68-70 (Kenneth J. Rothman & Sander
Greenland eds., Lippincott Williams & Wilkins 1998) (discussing strengths and
weaknesses of different kinds of epidemiological studies).
165. See CRANOR, supra note 141, at 200-04 (recognizing different methods
that firms in regulated industries adopt or utilize to challenge accuracy and rele-
vance of negative evidence in court).
166. See CRANOR, supra note 144, at 121 (highlighting detrimental effect of
delays in regulation); see also Sara M. Hoover et al., Improving the Regulation of Car-
cinogens by Expediting Cancer Potency Estimation, 15 RISK ANALYSis 267, 267-80 (Apr.
1995).
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Any exposure of developing fetuses and children to toxic sub-
stances may well be greater than those for adults, as they currently
appear to be for PBDEs. If agencies are maneuvered into requiring
human studies to show risks of harm, they could utilize cohort epi-
demiological designs to study children already known to have been
exposed to a toxicant prenatally or neonatally and follow them for
sufficient time to permit subtle adverse effects to manifest. Case-
control studies could also be used to study children with subtle
learning disability problems to determine what exposures or lifes-
tyle factors are associated with the adverse effects. Neither cohort
nor case-control studies are easy to use in order to detect subtle
effects arising from developmental or early childhood exposures.
Human epidemiological studies are generally insensitive and are
quite limited in detecting subtle differences between healthy and
adversely affected children. Currently, there is a national chil-
dren's cohort study aimed at identifying factors that contribute to
adverse developmental effects. 167 Even if the studies are able to de-
tect toxicants' adverse effects, many children, defacto serving as re-
search subjects, will suffer the developmental effects in the process
of establishing that exposure causes harm.
If animal studies are utilized, to the extent that efforts to re-
duce exposures to carcinogens are typical, regulated parties will ar-
gue that animal studies do not indicate potential human harm or
do not accurately measure exposures that will pose harm to
humans. Regulated parties will focus on the differences between
humans and animals, arguing that few reliable inferences can be
made from animals to humans. In the case of developmental toxi-
cants, critics of testing will argue that there are developmental dif-
ferences between humans and different animals, such as rats, mice,
guinea pigs, or rabbits.1 68 Selecting an appropriate model for study
is therefore challenging. Despite this, there appears to be substan-
tial positive predictive value in animal studies for human harm (75
percent to one hundred percent).1 69 This degree of accuracy
167. Grandjean & Landrigan, supra note 25, at 9 (discussing national chil-
dren's cohort study).
168. See SCHARDEIN, supra note 23, at 40 (indicating that, "animal studies can-
not predict effects in humans with absolute certainty"). Suitably designed studies
give some indication of risk, but they do not guarantee safety to the fetus. Id.
169. Id. (using empirical tests to indicate scientific value and accuracy from
animal testing). Positive predictive value in this case appears to be the number of
animal studies that correctly predict human harms divided by the number of posi-
tive predictions, both those that correctly predict harm and those that mistaken
predict harm (Correct predictions from animals/ (correct predictions + incorrect
predictions)).
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seems defensible for public health protections, because it is better
to correctly identify between 75 and 100 percent of the develop-
mental toxicants by means of animal studies than to wait for slow,
science-intensive, insensitive human epidemiological studies to try
to identify them after the fact of exposure.
Thus, our mammalian relatives provide practical models on
which to conduct actual experiments with toxicants (humans are
unacceptable research subjects). Moreover, as in other areas there
are substantial similarities in mammalian biology in order to pro-
vide insights and evidence for likely human harm. Those wishing
to restrict studies of developmental toxicology to humans will have
to live with the consequences of harm to their fellow citizens and
their children while long-term, insensitive epidemiological studies
are conducted on people in an attempt to detect subtle (and not-so-
subtle) adverse effects. If these studies are even scientifically plausi-
ble, some diseases may not manifest themselves until middle or old
age, and generations of cohorts will have been exposed for which
such scientific and legal policies would have to answer.' 70
Is there a better way to go, so we do not have to rely upon time-
consuming, corroborative science with imprecise, insensitive studies
in order to prevent our children from suffering harm? If products
cause adverse effects, the harm will not be halted until exposures
are reduced sufficiently to eliminate the harm and to satisfy the law
and appellate courts in question. For developing children, many
years of exposed cohorts would suffer adverse effects before expo-
sures causing harm could be reduced or eliminated. While there
are some legal reforms that would assist in addressing these issues,
this Article presents two alternative moral conceptualizations of
these issues that will lead to different legal approaches.' 7'
V. AUTONOMOUS CHOICES IN USING LIFESTYLE DRUGS
We can begin to appreciate some of the rights citizens have or
should have over aspects of their life in the regulation of toxicants
by considering a proposal by Margaret Berger and Aaron Twersky
for the reform of part of tort law, otherwise a bastion of harm-
based, post-market "regulation" of toxicants. They recommend re-
forming part of tort law, calling attention to the rights citizens
170. Schwartz & Stewart, supra note 35, at 671 (citing concern that lead cur-
rently in citizens' bodies will cause future detrimental health effects).
171. See generally Carl F. Cranor, Some Legal Implications of the Precautionary Prin-
ciple: Improving Information Generation and Legal Protections, EUR. J. ONCOLOGY 31, 41-
44 (2003) (proposing various legal reforms to provide monitoring mechanisms for
exposure effects and disease).
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should have over drugs that they voluntarily take for lifestyle pur-
poses, e.g., such as Viagra to enhance sexual potency. "Lifestyle
drugs," drugs that are not medically necessary to one's health, are
drugs that enhance one's life in various ways. These authors have
argued that
the time has come for courts to recognize the right of pa-
tients to informed choice about risks associated with the
use of a drug, a right that does not require plaintiffs to
prove that the toxic agent was the cause of the plaintiffs
harm. To do so we shall suggest a new paradigm for this
informed choice cause of action that protects the right of
patient autonomy, yet does not impose liability for the full
extent of damages as would be the case when a plaintiff is
able to prove causation. Absent recognition of a right
predicated on informed choice, plaintiffs will be deprived
of vital information necessary to make critical decisions re-
garding lifestyle drugs and pharmaceutical manufacturers
will have little incentive to discover and warn about uncer-
tain risks. With causation standing as a barrier to recov-
ery, defendants will sit back confident that liability is
highly unlikely to attach to conduct that is admittedly
negligent.172
Thus, Berger and Twersky argue that tort law imposes a duty
on a manufacturer to warn consumers against risks posed by a drug
that are uncovered by research after products are in commerce so
that individuals can make informed decisions before taking the
drug. This duty is breached under current law when a risk is of
sufficient consequence that reasonable persons would seek to be
warned against such risks. 1
73
The Learned Hand risk-utility test requires that an actor
take precautions to warn against even remote risks when
the gravity of the foreseeable harm is great. That there be
a causal nexus between the defendant's wrongful conduct
and the harm suffered is a principle deeply ingrained in
tort jurisprudence and we do not question that hoary
maxim. However, in the context of toxic tort cases, to re-
172. Margaret A. Berger & Aaron D. Twersky, Uncertainty and Informed Choice:
Unmasking Daubert, 104 MICH. L. REv. 257, 259 (2005) (arguing that citizens must
be given accurate information about toxicants in products in order to make in-
formed autonomous consumer choices).
173. Id. at 267-68 (discussing breach of legal duty).
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quire that the plaintiff actually demonstrate that the toxic
agent caused the plaintiff's harm flies in the face of the
well-recognized right of a patient to make an autonomous
decision as to whether she wishes to expose herself to even
an uncertain risk. The assault on autonomy is especially
egregious in the case of lifestyle drugs where the drug has
little therapeutic value. In such cases one can predict with
a high level of confidence that a patient informed of the
potential risk would almost certainly have opted against
taking the drug and subjecting herself to the risk.174
Implicit in the Berger/Twersky proposal is an individual's right
to make autonomous decisions about risks associated with lifestyle
drugs. This idea of autonomy is deeply embedded in our moral,
legal and civic culture. American society insists on patients being
informed so they can make autonomous choices when undergoing
medical procedures, operations, and clinical trials. Informed con-
sent has been part of medical malpractice law for more than three
decades, 175 and part of medical testing guidelines for at least sixty
years.' 76 Moreover, courts have endorsed an informed choice
cause of action in products liability law:
In Davis v. Wyeth Laboratories, Inc., [399F2d 121 (9th Cir.
1968)] the defendant manufacturer sold polio vaccine
without warning of the risk that one person in a million
would contract polio from taking the vaccine. The court
held that the manufacturer had a duty to warn the con-
sumer of the risks involved and that the failure to meet
this duty rendered the drug unfit and unreasonably dan-
174. Id. at 268 (emphasis added) (presenting therapeutic damages for lifes-
tyle damages). See generally United States v. Carroll Towing Co., 159 F.2d 169 (2d
Cir. 1947); ARNO C. BECHT & FRANK W. MILLER, THE TEST OF FACTUAL CAUSATION
IN NEGLIGENCE AND STRICT LIABILITY CASES (1961); DAN B. DOBBS, THE LAW OF
TORTS 166-69 (West Group 2000); Wex S. Malone, Ruminations on Cause-in-Fact, 9
STAN. L. REv. 60 (1956); Richard W. Wright, Causation in Tort Law, 73 CAL. L. REv.
1735 (1985).
175. See generally TOM L. BEAUCHAMP & LEROY WALTERS, CONTEMPORARY ISSUES
IN BIOETHICS 139-55 (Tom L. Beauchamp & LeRoy Walters eds., Thomson 6th ed.
2003) (discussing history and practicability of informed consent in medical mal-
practice law).
176. See id. at 354-57. See also Library of Congress, Trial of War Criminals
Before the Nuernberg Military Tribunals Under Control Council No. 10. (Oct.
1946-April 1949), http://www.loc.gov/rr/frd/Military_Law/NTs war-criminals.
html; World Medical Association, Declaration of Helsinki: Ethical Principles for
Medical Research Involving Human Subjects (Sept. 10, 2004), http://www.wma.
net/e/policy/b3.htm (identifying informed consent principles within text of inter-
national codes and declarations).
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gerous within the meaning of [§] 402A of the Restatement
(Second) of Torts) 77
In addition, courts have recognized a cause of action for battery
when medical experiments on DES were conducted on patients
without their knowledge.178 In order "to state a cause of action for
battery, the plaintiffs must allege intentional acts by the defendants
resulting in offensive contact with the plaintiffs' person, and the
lack of consent to the defendants' conduct .... [Moreover,] the
actor must 'intend to cause the other, directly or indirectly, to come
in contact with a foreign substance in a manner which the other
will reasonably regard as offensive.' 1 79 The court found that "the
administration of a drug without the patient's knowledge comports
with the meaning of offensive contact. Had the drug been adminis-
tered by means of a hypodermic needle, the element of physical
contact would clearly be sufficient. We believe that causing the pa-
tient to physically ingest a pill is indistinguishable in principle."180
Finally, tort law recognizes similar assaults on autonomy by
granting dignitary damages "for assault, battery and false imprison-
ment without regard to whether the plaintiff suffered physical
harm."181 The need for informed consent and the importance of
personal autonomy has been much more widely utilized in moral
philosophic discussions since its rise to prominence in the medical
ethics context and, one might even say, since John Stuart Mill wrote
about the importance of autonomy in On Liberty in 1859.182
Berger and Twersky recommend reduced compensation for vi-
olation of informed consent for risks from lifestyle drugs, presuma-
bly because full-fledged harms may not have occurred, but are still
violations of rights. Compensation for violation of informed con-
sent is recognition that a wrong has occurred, but perhaps not yet a
physical harm or not as serious a harm as when a risk fully material-
177. Berger & Twersky, supra note 172, at 273 (citing case law to emphasize
the importance of informed consent, even in extremely low risk circumstances).
178. Mink v. Univ. of Chi., 460 F. Supp. 713, 718 (1978) (furthering impor-
tance of informed consent in cases where medicine was used on patients without
their knowledge).
179. Id. (quoting in part the Restatement (Second) of Torts section 18, Com-
ment (c) at 31 (1965)) (detailing informed consent and intent requirements nec-
essary to hold firm accountable in torts).
180. Id. (defining offensive contact in medical profession).
181. Berger & Twersky, supra note 172, at 282 (discussing dignitary tort dam-
ages); see generally DAN B. DOBBs, THE LAW OF TORTS 42 (West Group 2000).
182. See generally JOHN STUART MILL, ON LIBERTY (Currin v. Shields ed., Pren-
tice Hall PTR 1956) (discussing the importance of autonomy in moral
philosophy).
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izes. 183 Thus, citizens should have a cause of action and compensa-
tion for a violation of informed consent and should receive higher
compensation according to the degree of harm caused.
Autonomous choices as articulated by Berger and Twersky pre-
suppose: (1) that the person has moral and legal rights in this area
of their lives; (2) that they have or should have more specific moral
and legal authority to exercise this control over lifestyle drugs that
they voluntarily consume; and (3) that the person should have
knowledge of risks from such drugs in order properly to exercise
their rights in this respect. Berger and Twersky's paper, strongly
reinforced by the court's decision in Mink, provides a useful com-
parison with the inevitable entry of chemicals in citizens' bodies.
VI. APPROACHES TO ADDRESSING INVASIONS OF MANUFACTURED
CHEMICAL SUBSTANCES
A. Use of Legal Presumptions
Given the scientific case for the increased chances of develop-
mental harm to children, one legal strategy to prevent increased
chances of developmental harm to children is that scientific evi-
dence supports the legal presumption that in utero and perinatal
exposures to substances have the potential to cause harm during
development. Consequently, manufacturing firms would have the
burden of proof, as opposed to government agencies, and would
have to show, on the basis of animal and other non-human evi-
dence, that the exposures would not pose risks of harm to develop-
ing children before the products entered commerce or the
environment or in order to permit existing substances in commerce
to remain. This approach would be based on the idea of a legisla-
tively created legal presumption.
Legislative bodies and courts often create presumptions. For
instance, in criminal law Congress created a presumption that a
person arrested in the United States in possession of marihuana or
183. See Berger & Twersky, supra note 172, at 285 (comparing invasion and
negligent infliction of emotional distress). In explaining their view, Berger and
Twersky state, "[w]e thus advocate a cause of action for negligent infliction of emo-
tional distress when plaintiff is deprived of an informed choice about material risk
even if the causation of the actual physical injury cannot be established with the
certainty demanded by traditional causation norms. We would expect that the
greater the materiality of the risk, the greater the damages assessed against the
defendant. And we would also expect that greater damages would be assessed if it
were found that a defendant acted in bad faith in refusing to reveal material risk
information. The sense of betrayal and hurt suffered by a plaintiff deprived of
meaningful choice cannot be divorced from the conduct of the defendant who was
responsible for the deprivation." Id.
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heroin "unless explained to the jury's satisfaction, 'shall be deemed
sufficient evidence to authorize conviction' for smuggling .... buy-
ing, selling, or facilitating the transportation, concealment, or sale
of the drug, knowing that it had been illegally imported."18 4 Con-
gress therefore created the presumption that such a person is a
drug smuggler and dealer, not a mere purchaser of drugs for his or
her own use. Thus, the penalties would be much greater for im-
porting and dealing than for mere purchase for personal use. If
such presumptions can be used for the criminal law where there is a
much greater concern for individual rights, they could also be uti-
lized to protect our children with respect to toxicants.
If there were a presumption that chemical substances could
enter the uterus and potentially pose risks to the fetus, companies
would have to provide evidence, not mere assertions, to rebut it. If
a presumption were used for manufactured products, however, it
might be criticized as non-scientific, simply because it would be leg-
islatively created, despite the powerful scientific case that manufac-
tured chemical products invade and expose fetuses in utero and
neonatally. This need not be a fatal flaw, and may seem somewhat
awkward, but legislatures have this authority. There are two addi-
tional legal models, however, that are preferable because they bet-
ter capture moral concerns.
One strategy is based on the idea of trespass, or more broadly,
interference with one's rights over one's person and possessions.
The other strategy is based on jurisdictions placing reasonable con-
ditions on permissions for companies to create chemical products
for commercial products. Similar to a "permission" model, and
much like the REACH legislation in Europe, if there is no safety
data about products for developing children or adults, companies
may not market their products and expose citizens. The slogan is
no data, no market. The remaining sections of this Article will dis-
cuss some of the implications of the trespass view and then the per-
mission view.
184. Turner v. United States, 396 U.S. 398, 404 (1970) (citing 21 U.S.C.
§ 176(a) (2006)) (stating presumption existence).
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B. The Trespass Model
1. Background
The doctrine of trespass provides much of the historical back-
ground of torts, 185 but what remains in contemporary tort laws as
trespass largely concerns real property:
Historically, the requirements for recovery for trespass on
land under the common law action of trespass were an in-
vasion (a) which interfered with the right of exclusive pos-
session of the land, and (b) which was a direct result of
some act committed by the defendant .... An interfer-
ence with this exclusive possessory interest brought about
in a direct way from an act committed by the defendant
was regarded legally as actionable. This was so even
though the invasion caused no harm and even though the
defendant was not at fault in causing the invasion ....
The most important of the trespass rules to survive [from
historical doctrine] was that which imposed liability for in-
vasions of property which were neither intended nor neg-
ligent. The defendant was not liable so long as he had
done no voluntary act, as where he was carried onto the
plaintiff's land by others against his will.186
Moreover, a trespass could be sustained "without proof of any
actual damage. From every direct entry upon the soil of another,
'the law infers some damage; if nothing more, the treading down
grass or herbage."' 8 7 "The action was directed at the vindication
of the legal right ... ."188 In addition, "one who trespasses upon the
land of another incurs the risk of liability for any bodily harm which
is caused to the possessor of the land or to members of the house-
hold by any conduct of the trespasser during the continuance of
the trespass."'189
More importantly an invasion of the right to possession results
if one enters the property without "authorization," without paying
for it, or without permission.1 90 These terms are important because
it is clear that one who has the right to exclusive possession of prop-
185. See W. PAGE KEETON ET AL., PROSSER & KEETON ON TORTS 28-30 (W. Page
Keeton ed., West Publ'g Co. 5th ed. 1984) (discussing historical place of trespass in
tort law).
186. Id. at 67-68 (discussing trespass).
187. Id. at 75 (explaining trespass).
188. Id. (emphasis added) (discussing legal rights).
189. Id. at 76 (discussing bodily harm and trespass).
190. See KEETON ET AL., supra note 185, at 70-71 (detailing aspects of trespass).
48
Villanova Environmental Law Journal, Vol. 19, Iss. 2 [2008], Art. 1
https://digitalcommons.law.villanova.edu/elj/vol19/iss2/1
2008] REGULATORY MODELS FOR PROTECTING CHILDREN
erty has the important associated right to choose who can be on it or the
right to authorize the presence of others on it or the right to license them to be
there.
The trespass doctrine principally concerns real property, but
some case law extends that right to persons. 91 Trespass encom-
passes not only the deposition of persons or things, but also of mol-
ecules and particles on another's land.192 More importantly,
however, the idea of trespass rests on a deeper consideration, re-
lated to the rights over aspects of one's life and the right to author-
ize others to enter those protected areas. For example, Arthur
Ripstein's following narrative suggests that harmless trespass into
your house is a wrong:
I let myself into your home, using burglary tools that do
no damage to your locks, and take a nap in your bed. I
make sure everything is clean. I bring hypoallergenic and
lint-free p[ajamas and a hairnet. I put my own sheets and
pillowcase down over yours. I do not weigh very much, so
the wear and tear on your mattress is nonexistent. By any
ordinary understanding of harm, I do you no harm ....
You[r] objection is to my deed, my trespass against your
home, not to its effects.193
Other violations of a person's right to authorize entry onto
one's property or to authorize intrusions on one's person include:
(1) unknown fluoridation of your teeth at the dentist's office even
though you are philosophically opposed to it; (2) a doctor's unau-
thorized touching a patient in an intimate place while he or she is
sedated; and (3) harmless medical experiments performed on un-
conscious patients that leave no trace, do no obvious harm, and are
without permission.194
To add to this point, consider the following hypothetical. Sup-
pose you dispose of some trichloroethylene (TCE) from home ex-
191. Sullivan v. Dunham, 55 N.E. 923, 926-27 (N.Y. 1900) (extending trespass-
ing liability to personal injury caused by debris from blast on one's own property).
192. See Martin v. Reynolds Metals Co., 342 P.2d 790 (Or. 1959) (holding
manufacturing operation which caused fluoride gases and particulates to become
airborne and settle upon owner's land constituted direct trespass); Borland v.
Sanders Lead Company, Inc., 369 So.2d 523 (Ala. 1979) (characterizing dangerous
accumulation of lead particulates and sulfoxide deposits as trespass).
193. See Arthur Ripstein, Beyond the Harm Principle 34 PHIL. & PUB. AFF. 215,
218 (2006) (discussing harmless trespass as trespass nonetheless).
194. Id. at 227 (comparing to harmless invasions).
299
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periments in a hot tub without permission.1 95 TCE is a carcinogen,
but diluting small amounts in a hot tub reduces any risk of harm.
Have you done anything wron. You did not harm those who were
exposed to TCE in the hot tub, or perhaps even pose a risk of harm.
But the TCE invaded, or "trespassed" on the hot tub owner's prop-
erty and perhaps on those who used the hot tub. It was present on
the property and therefore exposed others to the chemical without
authorization. Following the reasoning in Mink, the disposal of
TCE could be thought of as a battery, exposing the hot tub users to
a chemical without permission just as Patsy Mink was exposed to
DES without permission. 196
Similarly, if a doctor conducts medical experiments on patients
by exposing them to molecules without their permission as the Uni-
versity of Chicago did to Mink and others, the doctor has trespassed
on or battered and wronged them. Finally, consider another exam-
ple, more like human invasions of chemical substances. Suppose a
chemist has an unknown substance. The chemist does not know
whether it is toxic or not, a poison or not, or totally benign; it might
even be beneficial if it enters your body. If the chemist puts this
substance into another's drink or into the environment knowing it
will enter his or her body without informing the person and asking
permission, has the chemist not wronged the victim by simply put-
ting it into his or her drink?
This Article does not propose principles for the criminal law,
as Ripstein does. Nor does it propose a principle for the tort law.
Instead it suggests a model by analogy with trespass to guide regula-
tory policy in governing toxic exposures. The above examples con-
tain a common thread: a person is wronged even though no harm is
done because the pertinent invasion violated a right without proper
authorization by the person invaded, either a specific or a more
general authorization. Ripstein has argued that an unauthorized in-
vasion of citizens' bodies or property by others is a wrong analogous
to a trespass.197 This Article suggests by examples that invasion by
potentially toxic substances is analogous to a trespass or even a bat-
tery. Morally, citizens should regard invasion of their bodies with-
195. See Raymond Neutra, Risk Assessment, 237 Sci. 235 (Jul. 1987) (detailing
experiment).
196. See Mink, supra note 178, at 718 (discussing action under theory of bat-
tery taken by women given diethylstilbestrol against university and manufacturer of
drug).
197. See Ripstein, supra note 195, at 228, 233-36, 241-42 (explaining how vari-
ous unauthorized invasions of persons or their property somewhat resembles
trespass).
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out permission by humanly created substances as a trespass. The
deeper point is the idea of a person having considerable rights or
authority, or as Ripstein puts it, "sovereignty" over her life and
property. 98 The invasion of a person's sovereignty or authority by
invading her person or her property is a trespass into areas of her life
over which she has or should have sovereignty or substantial authority. 99
Thus, he argues for a sovereignty principle, noting that "the only
legitimate restrictions on conduct are those that secure the mutual
independence of free persons from each other."200 This Article
does not follow out such a general idea, but it may hold promise for
the view suggested here.
When citizens have an explicit right to either accept or reject
exposure to substances such as lifestyle drugs, as Berger and Twer-
sky argue, they should be informed of any risks that have emerged
since the drug was approved, so that they have a realistic opportu-
nity to exercise that right. 20 1 Any rights citizens have or should
have over their bodies and the drugs they take is empty unless they
possess the requisite knowledge of the risks involved. Thus, knowl-
198. Id. at 229-45 (discussing concept of sovereignty and some of its
implication).
199. See id. at 231, 233-36, 241-42 (showing various ways wrongs consist in vio-
lations of areas of life over which one should have authority).
200. Id. at 229 (discussing restrictions on conduct). He adds to this view as
follows:
You are independent if you are the one who decides what ends you will use
your powers to pursue, as opposed to having someone else decidefor you ... You
remain independent if nobody else gets to tell you what to do. .. [Moreo-
ver, the interest in independence is] a distinctive aspect of your status as a
person, entitled to set your own purposes, and not required to act as an
instrument for the pursuit of anyone else's purposes... Each person is
free to use his or her own powers to set and pursue his or her own pur-
poses, consistent with the freedom of others to use their powers to set
their purposes. Id. at 231 (Emphasis added).
[In short] the sovereignty principle says that each person is entitled to
use his or her own powers as he or she sees fit, consistent with the ability
of others to do the same. The consistency is achieved through the joint
ideas of non-interference and voluntary cooperation. Nobody is allowed
to use or damage another person's means without their permission. If
everyone forbears from doing these things, each person is independent
of all the others.... Wrongdoing takes the form of domination. Id. at
233.
[P]art of being free to use your powers to set and pursue your own pur-
poses is having a veto on the purposes you will pursue.... When I usurp your
powers, I violate your sovereignty precisely because I deprive you of that veto.
Id. at 234-35 (emphasis added).
201. See Berger & Twersky, supra note 172, at 259 (explaining risks emerging
from research into Bendectin and Parlodel, two "lifestyle" drugs, but whose risks
were not sufficient to support tort cause of action for harm, but were risks patients
would likely want to know before ingesting).
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edge of the risks from products is a condition of a credible exercise
of their rights.
Berger and Twersky's issue in torts is not the problem that
many citizens face concerning protections from involuntary chemi-
cal invasions. The CDC's biomonitoring program and the Faroe
Islands Conference on the human health effects of developmental
exposure to environmental toxicants together have identified the
extent of involuntary, uninformed invasions, as well as risks from
invasions to fetuses, developing children, and, of course, adults.
Citizens are generally not aware of, nor do they have individual con-
trol over chemical invasions in the same way they have choices to
ingest lifestyle drugs. Citizens could make political decisions in the
future about how the law should address such substances, if they
understood the issues.
This Writer does not want to be an alarmist about the chemical
invasions, but it is a matter of serious concern. Some substances
pose no risks or harm, but others do. Some substances enter our
bodies through the ingestion of foods and water. Many of these
substances contain nutrients the body needs. Others are naturally
occurring substances that might enter our bodies through ingestion
or through inhalation. Some substances, however, might enter citi-
zens' bodies as a result of their living near industrial activities that
concentrate naturally occurring substances that pose risks.20 2 Some
substances in our bodies are not naturally occurring substances at
all, but are rather industrial chemicals created for specific pur-
poses, such as endocrine mimicking chemicals in plastic bottles or
other products, organochlorine pesticides, flame retardants
(PBDEs) in furniture, beds and computers, and so on. Still other
substances may be the by-products or contaminants of other manu-
facturing processes such as smelting, but invade our bodies and
pose substantial potential risks, such as arsenic, dioxins or polyaro-
matic hydrocarbons. Indeed, considerable care is needed to craft
an effective substance invasion policy because they come from so
many different sources. Accordingly, the following section will fo-
cus on possible policy responses to these concerns.
2. Policy Proposals
What might be a morally appropriate policy for humanly cre-
ated substances that invade our bodies or trespass on us? Industrial
chemicals invade even if at present citizens strongly would prefer to
202. Examples of this would include smelters that concentrate metals such as
arsenic, cadmium or mercury.
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prevent this. If citizens cannot make individual decisions about and
control whether industrial chemicals enter their bodies, how should
they think about the involuntary invasion of potentially toxic
substances.
This problem bears some similarities and some dissimilarities
to trespass. If someone harmlessly trespasses on property, although
the land owner might prefer to control access, he or she is not al-
ways able to exclude trespassers by posting warnings, creating enclo-
sures to resist entry, or locking doors. Nonetheless, the trespass is a
wrong precisely because he/she did not authorize it. That is, a trespass
occurred even though it is difficult physically to prevent it. In this
respect trespass on a person's property resembles chemical entries
into our bodies.
The creation of new substances and their release when they are
known to invade human bodies are also deliberate acts akin to trespass
on property.20 3 That is, someone knowingly created the substance,
and given the tiny size of molecules, knew or was practically certain
that these substances would invariably invade human bodies. More-
over, the deliberate creation and knowledge that a product will in-
vade resembles the intentionality needed for trespass. 20 4
Consequently, it is plausible to argue that the creation of chemical
substances known to invade bodies is an instance of "an intent to be
[in the body] where the trespass allegedly occurred," analogous to
the presuppositions of trespass (or even battery) in tort law.20 5
An ideal policy, of course, would be no invasion without ex-
plicit permission; that is the moral basis of human medical experi-
mentation and the informed consent doctrine that goes along with
it,206 as well as the moral basis of battery and trespass on prop-
erty.20 7 This, however, is impractical because citizens do not have
the ability to choose or not choose whether individual chemicals
invade on a particular occasion, although they could collectively ad-
dress this politically. Moreover, the CDC biomonitoring shows that
nearly, but not quite all substances that are in the air, our food, our
203. New substances might also include naturally occurring substances that
are in much greater concentration than they typically are in nature.
204. See KEETON ET AL., supra note 185, at 73 (describing level of intent
needed for trespass). "The intent required as a basis for liability as a trespasser is
simply an intent to be at the place on the land where the trespass allegedly oc-
curred." Id.
205. Id. (discussing intent associated with trespass).
206. See Mink v. Univ. of Chi., 460 F. Supp. 713, 716-17 (1978) (discussing
traditional and modern view of informed consent as well as the two theories of
liability for unauthorized medical treatment; battery or assault and negligence).
207. This Author has a paper in progress on this topic.
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water, some things we touch, will enter human bodies, including
the placenta. None of these entries can generally be prevented. By
contrast, citizens' choices can prevent the entry of vaccines, lifestyle
drugs, and medicines.
To sharpen the issue, consider a hypothetical that bridges
some of the differences between involuntary chemical invasion of
industrial chemicals and Berger and Twersky's examples concern-
ing lifestyle drugs. Imagine a world in which persons had individual
control over the entry of chemical substances into their bodies.
Suppose we had an invisible, partially chemically impermeable
cloak, similar to the children's book character Harry Potter's invisi-
bility cloak, that blocked the invasion of many chemical sub-
stances.20 8 Suppose we could program it to exclude substances, but
this operation was fairly difficult to carry out. Suppose also that it
permitted the entry of all chemical substances unless we program-
med it to exclude individual substances. If we had this kind of lim-
ited and somewhat burdensome individual control, it would suggest
a strategy toward inevitable invaders. In the imaginary cloak world,
would we not want to know which environmental chemicals would
permeate our cloak and what their properties and risks would be?
In our actual world, would we not want to know which created
chemical substances and highly concentrated naturally occurring
(harmful) ones that would inevitably invade were toxic and posed
risks of harm, potentially disrupting our biological functioning?
Unfortunately, we do not have such cloaks. Nonetheless, this
hypothetical suggests that it is reasonable to require product manu-
facturers to conduct certain tests on their products, so that the pub-
lic and regulatory agencies will have knowledge about the
substances and their risks. We might imagine a kind of surrogate
"Harry Potter test." What knowledge would we require about sub-
stances to justify programming our chemical cloak to preclude
invaders?
The preceding discussion suggests a second best policy. The
community could permit by legislation the creation of products that
invariably would trespass, but only if testing evidence provided rea-
sonable assurance that there would not be significant risks from the
invasions and a public agency certified the test results and approved
entry into commerce. Such legislation, in effect a social contract,
would permit companies to place their products in commerce, but
only on condition that they conducted specified tests, to be
208. J. K ROWLING, HARRY POTTER AND THE DEATHLY HALLOWS (Bloomsbury
2007) (describing invisibility cloak).
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sketched below, to determine whether substances will a) invade;
and b) pose risks or harms to humans. Based on the tests a public
agency would then review the results and permit them into com-
merce if they posed no significant risks. Children, newborns, and
developing fetuses are especially vulnerable and extremely impor-
tant to protect. Consequently there would need to be testing specif-
ically designed for their protection.
Failure to test for potential risks is analogous to medical exper-
iments on humans without proper preparation and assurances of
safety of the experiment and it is just as serious. It might even be
more serious since medical experiments are typically conducted to
determine beneficial health effects, but industrial chemical prod-
ucts are not created with beneficial health effects in mind for those
they might invade.
Test results will vary; some invaders will be innocuous, others
will be quickly and innocuously expelled through breathing or
other waste-removal procedures. They will neither stay long nor
metabolize into harmful by-products during their stay. For such
substances, no further testing may be needed.
Not all substances that enter our bodies are easily addressed,
however, and some substances inevitably will remain. Some will ac-
cumulate and some that accumulate will pose risks, but some may
not. Some that remain or accumulate will cause harms to adults
and some that accumulate may not cause harm to adults, but could
harm developing children, such as low-level lead, PCB or pesticide
exposures. In addition, some substances that are quickly expelled
may be metabolized or otherwise broken down into harmful by-
products before they are expelled. 20 9
Similar tests should also be provided to discover whether sub-
stances can invade the womb or breast milk, and, if they can, then
additional tests should be conducted to discover whether they cause
risks or harms to human developmental processes. In each case
without any testing for invasion, any entry into the womb or breast
milk would be unauthorized.
Recall the trespass analogy which suggests the testing strategy.
One wrong of a trespass is an unauthorized invasion or violation of a
right. By analogy there should be no presumption of moral innocence
for the invasion. 2 10 Although the primary wrong in the trespass
209. Such as polycyclic aromatic hydrocarbon's (PAH's).
210. PROSSER & KEETON ON TORTS suggests that in trespass, a cause of action
"could be maintained without proof of any actual damage. KEETON ET AL., supra
note 185, at 75. From every direct entry upon the soil of another, 'the law infers
305
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analogy is the unauthorized invasion, there are secondary (and po-
tentially just as serious) wrongs when invasions create risks of harm
or actually contribute to harm. Consequently, those who create
and distribute compounds that invade our bodies should be required
to engage in appropriate testing to help ensure against other wrongs (risks
or harms), secondary to the invasion. Commercialization and public
release of products could be deemed appropriately authorized if
there was appropriate testing for entry into human or mammalian
bodies, and subsequent testing revealed no significant risks of harm
to adults, fetuses, neonates or developing children, and an impar-
tial government agency had reviewed the tests and authorized entry
into the market (or for existing chemicals, authorized their remain-
ing in the market). 211
When substances test positive for risks or harms, this would
provide a basis of further regulation to prevent the serious secon-
dary wrongs before substances could enter the market if they were
new or to prevent their remaining there, if they were already pre-
sent. Moreover, if products are permitted into commerce resulting
in exposures, there should be close monitoring of them to catch
some damage; if nothing more, the treading down or grass or herbage.'" Keeton,
supra note 185, at 75 (discussing the wrong of trespass and minor role of harm).
On the harm principle, roughly, there is a presumption of moral innocence unless
there is harm or risk of harm. The harm or risk of harm is the primary wrong. Id.
211. More specifically as examples for testing, agencies could reasonably re-
quire firms to address at least the following issues about which science knows
before receiving agency approval to enter or remain in commerce:
" Whether when companies' products invade, are the kinds of substances
that, although they may be expelled relatively quickly, are like PAHs
that may be metabolized into more toxic compounds, such as epoxides,
during their elimination.
* Whether, when they invade they create precursor conditions that could
develop into future harm or create conditions for future harm. For
example, very low levels of benzene suppress the immune system; child-
hood exposures to ozone "restructure the lungs." Both invasions may
lead to harm in the future.
" Whether when they invade, they are likely to remain in our bodies. For
example, are they lipophilic or otherwise likely to attach to receptors or
tissues in our bodies and potentially pose problems, e.g., as do DDT,
PCB's, chlorinated or halogenated compounds of higher molecular
weight-PBDEs, PBBEs, as well as some of the metals, e.g., mercury,
lead and cadmium?
* Whether when they invade, their presence over time is likely to cause
further injury. For example, cadmium's harm to the respiratory system
is a function of time and level of exposure.
" Whether with accumulation, they are likely to pose risks or contribute
to harm immediately or later in life as do many persistent bioaccumulating
substances.
This Author owes some of these examples to David A. Eastmond, Chair Environ-
mental Toxicology, personal communication, November 15, 2007.
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any further risks or harms as early as possible.212 Additionally,
there should be legal provisions authorizing relatively quick re-
moval if secondary risks or harms appear.213
C. The REACH "Permission" Model.
Another alternative for addressing products that pose risks to
developing fetuses, newborns and children is a "permission" model,
similar to the recently passed REACH legislation in Europe.
2 14
REACH is the acronym for the Registration, Evaluation, Authorizsa-
tion and Restriction of Chemicals. 215 This complex piece of legisla-
tion requires the registration and testing of some 30,000 new and
existing chemicals in order to determine any risks or harms from
them.216 It contains a pre-market testing and approval law for new
chemicals, but it also requires similar testing and review of existing
substances so both new and existing substances are subject to the
same requirements. 217
The European Community has made the judgment that chemi-
cal products will not be permitted to be sold in the European
Union (EU) unless there is appropriate testing and assurances of
safety of the products sold therein. In a nutshell, the splendidly
simple epigram that captures this law is no (safety) data, no market.
If firms do not provide appropriate safety about their products, they
will not have permission to sell or distribute products in the EU.
The "European Union is aiming to achieve that, by 2020,
chemicals are produced and used in ways that lead to the minimiza-
tion of significant adverse effects on human health and the environ-
ment."218 It seeks to "ensure that substances of high concern are
eventually replaced by less dangerous substances or technologies
where suitable economically and technically viable alternatives are
available." 219 Responsibility for testing and ensuring the safety of
212. See Cranor, supra note 171, at 41-46 (discussing need to monitor sub-
stances for toxic effects and to have reasonably quick means of removing them
from commerce in order to best protect ourselves).
213. Id. at 38 (discussing advantages and disadvantages of pre-market and
post-market statutes).
214. See generally Registration, Evaluation, Authorization and Restriction of
Chemicals (REACH), No. 1907 (2006) (U.K.) (stating general provisions of
regulation).
215. Id. (explaining acronym).
216. Id. (setting forth requirements of REACH legislation).
217. Id. (explaining in detail precise requirements).
218. Id. at Art. I, 4 (discussing European Union's goals).
219. See Registration, Evaluation, Authorization and Restriction of Chemicals
(REACH), No. 1907 (2006) (U.K.) at art. I, 12 (discussing purpose).
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the products rests with the manufacturers and importers. 220 And
the required testing and assurance of safety will be based on the
quantity of the product produced.2 21 EU authorization to place
products on the market should occur "only if the risks arising from
their use are adequately controlled, where this is possible, or the
use can be justified for socio-economic reasons and no suitable al-
ternatives are available, which are economically and technically via-
ble."22 2 The "restriction provisions" of REACH "should allow the
manufacturing, placing on the market and use of substances
presenting risks that need to be addressed, to be made subject to
total or partial bans or other restrictions, based on an assessment of
those risks."223
The number and generic types of tests needed for a specific
substance are based on the number of tons of production volume
as a surrogate for exposure.224 Moreover, the tests are cumulative:
any test required for small production volume also applies to larger
production volumes. For example, under REACH, developmental
toxicants products produced in the highest volume would need a
reproductive/developmental toxicity screen in one species, a devel-
opmental study, a two-generation reproductive study, and a long-
220. Id. at art. I, 18-19 (discussing who should be held legally responsible
for harm caused by substances). "Responsibility for the management of the risks
of substances should lie with the natural or legal persons that manufacture, im-
port, place on the market or use these substances." Id. at art. I, 18.
221. See id. at art. I, 28-29 (discussing safety and obligations of researchers to
develop testing requirements based on quantities of substances).
222. Id. at art. I, 22 (discussing use of substances based on socio-economic
reasons).
223. Id. at art. I, 23 (detailing aspects of REACH).
224. Approximate and high end numbers of tests needed for each level of
production are indicated in Table 1.
Table 1
Cumulative Developmental Tests Under REACH Based on Production Volume
>10 tons per >100 tons per >1000 tons per
>1 ton per year year year year
Physical- 14 14 17 17
chemical data
Environmental 1 4 10 13
fate
Ecotoxicology 2 4 12 16
data
Mammalian 6 14 18 24
toxicity-related
data
Summary taken from a presentation by David A. Eastmond, Chair, Department of
Environmental Toxicology, University of California, Riverside (Nov. 2007) (summarizing
types of tests under the REACH regulation).
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term (greater than twelve months) toxicity study, a study of repro-
ductive toxicity, a two-generation study, and a carcinogenicity study.
Whether this battery of tests will work to identify substances that
would cause sub-clinical developmental effects or risks depends
upon the tests that are required. Some knowledgeable observers of
the REACH legislation are skeptical about this, but the details of
the program will be importantly determinative. 225
With regard to testing the EU specifies some particular tests
that firms will need to utilize in order to provide reasonable assur-
ance of no significant developmental risks from toxicants.22 6 The
advantage of this is that the government agencies would choose the
tests to be followed and have some assurance that the chosen tests
were sufficiently protective for their purposes. REACH does permit
firms to present evidence of alternate testing protocols, if it can be
shown that they better serve the purposes or are more sensitive and
so on.
2 2 7
REACH shares with the trespass model the idea of testing prod-
ucts before they come into market, or testing those already in the
market, in order to determine whether or not they pose any risks to
adults, developing fetuses, newborns or somewhat older children.
In both cases an impartial government agency must find the test
acceptable, review the products for safety, and then grant or deny
their entry into (or continuation in) the market. In some respects
REACH is simpler than a trespass model because it rests on the idea
of permission; although the idea of appropriate permissions has a
role in both cases.
Under REACH companies do not have a right to manufacture,
sell, or distribute any goods in the EU that they think are appropri-
ate; their products may enter the market only by permission of the
EU, and that permission is conditional upon testing products and
ensuring their safety to the satisfaction of an agency.228 This makes
clear that access to a market is not a liberty right or a claim right,
but a permission granted by a country, provided some further con-
225. Conversation with Philippe Grandjean, University of Southern Denmark
and Harvard University, at the Faroe Islands Conference on Prenatal Program-
ming and Toxicity, May 24, 2007.
226. See Registration, Evaluation, Authorization and Restriction of Chemicals
(REACH), No. 1907 (2006) (U.K.) at L 396/339, L 396/352-53, L 396/364-66
(providing information on tests specified by EU).
227. See id. at art. I, 14 (describing alternate testing protocols).
228. See id. at art. I, 19-21 (stating that REACH permits substances to enter
market only after their safety has been ensured by various testing).
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ditions are satisfied concerning the safety of the products to be
marketed.
As noted above, under post-market laws, it is as if firms have a
legal right to market products in the United States unless and until
the products cause harms or risks of harm. The permission model
treats access to markets not as a right, but as a privilege, a much
different moral and legal relationship between a country and firms
seeking to do business within it, whether they are domestic or for-
eign firms.
D. Choosing between the Trespass and REACH Models
REACH has some attractive features. It is splendidly simple-if
there is no safety data for developmental and other adverse health
effects, company may not sell in the EU market. It reminds citizens
that those who create and sell products have no right to do so unless
they can assure the citizenry of the products' safety. Participation
in the market is conditioned on doing something for the citizenry
other than providing products-testing them to ensure health
protections.
The "trespass" model has other attractive features. It reminds
citizens of their substantial moral and legal authority over their lives
in a variety of dimensions, not just property. And, it reminds them
how their bodies can be invaded and that they have or should have
proper authority over them. It also reminds them of important re-
lations between citizens-one citizen may not cause humanly cre-
ated substances to invade the bodies of others without appropriate
assurance of the safety of the product that enters other citizens'
bodies.
The trespass analogy tends to model what the science is re-
vealing and reinforces the moral and legal rights on which citizens
should insist. Do substances invade human bodies, the womb or
breast milk to which children are exposed? If there is invasion,
does it cause harm or pose risks? It also appears to resonate with
citizens-there is some anecdotal evidence and news accounts that
when citizens learn about the presence of industrial chemicals in
their bodies, substances whose presence they have not authorized;
they feel "surprised," "concerned," "angry," or perhaps simply
wronged. 229 They might well feel as if they are experimental sub-
jects without having given their permission for the experiment.
229. Examples of such substances would include mercury compounds, PCB's,
polybrominated diphenyl ethers (flame retardants), organocholorine pesticides,
phthalates and bisphenol A (plasticizing agents), or perchlorate (a component of
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VII. FINAL POINTS ON THE BET
The title of this Article, "Do you want to Bet Your Children's
Health on Post-market Harm Principles?" asks something of a rhe-
torical question, given the scientific evidence and arguments
presented above. The arguments of this Article, however, rest on
some quite significant claims, all of which appear to be correct. If
one wishes to bet his or her children's health on one of these claims
not being true, those would be poor investments of money.
Should one bet that there will be no more contamination of
our bodies by manmade chemicals? This would be a bad bet to
make, since it seems quite plausible that such contamination will
continue except for the largest polymers.
Is one willing to bet that mothers will not share their chemical
burden in utero or through nursing? Again, this would be a bad bet
as a matter of basic biology. It seems highly likely that many chemi-
cal substances in women's bodies will pass through the placenta
into the womb and then later through the breast milk to develop-
ing infants. Some substances in mothers' bodies will not enter the
womb because of size, electric charge, and so on, but many will.
Perhaps not all substances present in mothers' bodies will enter
breast milk and expose their developing children, and not all will
follow the "calcium stream," but some will.
Is one willing to bet that children will not be more susceptible
than adults, more exposed on a body weight basis, or have fewer
defenses against chemical assaults than adults? Should one bet that
developing organ systems will not be as susceptible to toxic sub-
stances as they have in the past? These are very poor bets; there is
no reason to believe that children's basic biology will change radi-
cally in the near future or that we have bred a race of new humans
with super organ systems that will not be susceptible to toxicants.
Should one bet that there will be no other developmental toxi-
cants than those known to date? It is more difficult to know the
answer to this question, but again it appears to be a poor bet to
assume that all developmental toxicants are known and under-
rocket fuel). See e.g., Dave Newbart, Are You Being Poisoned? Five Volunteers Tested by
Environment Illinois Were Surprised to Find Out Their Bodies Contained Toxic Chemicals
- All from Using Everyday Products, CHICAGO SUN-TIMES, Nov. 9, 2007 (describing
some results of biomonitoring on five volunteers); Robert C. Pollack, Study Shows
Woman has Traces of 17 Toxic Chemicals in System, SHORE LINE TIMES.COM, Nov. 13,
2007, http://www.zwire.com/site/news.cfm?newsid=l9020618&BRD= 1630&PAG=
461&deptid=7736&rfi=6 (providing example of public concern); ENVrL. DEF.,
supra note 12, at 1 (indicating people from all walks of life are contaminated by
mixture of toxic chemicals).
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stood. It would also be an especially poor bet to count on post-mar-
ket laws catching toxicants before they cause harm. Quite the
contrary, these problems are just coming to light and it appears
highly likely that the more scientists look into the issues, the more
developmental toxicants they are likely to find. As scientists de-
velop the tools to identify more subtle adverse developmental ef-
fects, the more they are likely to find. This has occurred with such
diverse substances as lead, mercury, DDT, various plastics and endo-
crine disrupters. Moreover, as noted in section III (F) PBDEs are a
class of lipophilic, bioaccumulating substances that almost certainly
will cause the same kinds of problems that PCBs do. 230 Post-market
laws are simply not up to the task of preventing harms from PBDEs
or other developmental toxicants.
Is it a good bet that research has discovered all the substances
that can cause developmental problems at low concentration levels,
that no other substances will trigger cancer early as other sub-
stances have? This, of course, is much more difficult to know. As
research progresses in this area it appears that subtle adverse effects
are being discovered at quite low levels. This is certainly true of
lead, for which there appears to be no lowest level of toxicity in
utero. How many substances are sufficiently similar to lead for
which there is no lowest adverse effect level or only an extremely
low adverse effect level for developing fetuses and neonates? The
general biological principles that developing fetuses and newborns
are much more susceptible than adults does not make such a bet a
promising one.
Some might want to bet that mammalian research models will
have little biological relevance to humans. This is certainly a point
that manufacturers of products will argue, despite the fact that they
and other companies utilize the same kinds of studies in their own
research. Nonetheless, experimental mammalian studies are the
primary means by which scientists come to understand the toxicity
of substances. They are genuine scientific experiments and avoid
the need to conduct unethical experiments and chemical trespass
on humans. Moreover, biologists and toxicologists will continue
utilizing such studies for the foreseeable future; for the most part it
will be the best science available until superior short-term tests are
designed. Finally, without relying on animal studies and other non-
230. Hooper & McDonald, supra note 94, at 387 (discussing similarity of
PBDEs to PCBs). "PBDE toxicology resembles that of the PCBs. Some of the per-
sistent and bioaccumulative PBDE congeners seem likely to cause cancer and thy-
roid and/or neurodevelopmental toxicity, based on available PBDE toxicology
data and on structure-activity relationships with PCBs .... " Id.
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human tests, as a society we will put at risk many decades of cohorts
of children when we do not use experimental studies in order to
detect adverse effects in a timely manner.
Does the citizenry wish to bet that post-market laws that seem
so ineffective in addressing toxic risks to children will suddenly be-
come strikingly efficacious in this regard? This bet seems a non-
starter. Post-market laws have substantial scientific and legal bur-
dens of proof for agencies to overcome and too many incentives for
regulated companies to delay and frustrate testing, science and reg-
ulation. Business as usual seems not only risky, but probably harm-
ful to our children.
VIII. CONCLUSION
Under existing laws governing chemical substances citizens are
in large measure guinea pigs or experimental subjects. They are
guinea pigs to the extent that current laws permit the vast majority of
substances into commerce without significant testing (with drugs,
pesticides and new food additives partial exceptions), and then wait
for any risks or harms to be revealed as a result of human exposures
or non-human testing, which are typically slow to be conducted.
Perforce, citizens are experimental subjects in that defacto they be-
come one of the main testing grounds for the toxicity of products,
but without having authorized or consented to the exposures.
Moreover, to the degree that actual practice requires that human
harm must be scientifically demonstrated before regulatory action
is justified and exposures reduced or eliminated, citizens are guinea
pigs in a more robust sense.
Citizens are also the subjects of manufacturers' choices because
it is the manufacturers' decisions, not citizens' choices, that determine
whether citizens are invaded by chemical compounds for which ad-
equate testing has not occurred. Of course, it will be impossible or
impractical for citizens to become full sovereigns over their bodies
for each individual invasion where chemical substances are con-
cerned because there is no biologically practical way to exclude
them. Invasion is even worse when firms' decide to send chemicals
into the environment and inevitably into our bodies without under-
standing what their trespass can do to us.
We can move some way toward gaining greater civic control
over chemical exposures and greater individual rights over our bod-
ies and our lives by requiring no trespass without testing for both
invasion and risks, or no permission to send products into our com-
mercial markets (or permit them to remain there) without safety
313
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data and government approval. There should be no invasion of ex-
isting or newly created compounds or greatly concentrated natural
compounds from manufacturing processes without testing for what
they will do after invasion. Testing will help remove uncertainty
about their properties and help ensure that the primary wrong of
invasions do not carry with them secondary wrongs of harm or risks
of harm that can exacerbate the initial wrong of trespass. If inva-
sions pose harm or risks of harm, the substances should then be the
subjects of regulation to try to prevent the secondary wrongs. Were
the citizenry to take such steps through legislation it would make
progress in going from guinea pigs or subjects to sovereigns over
their lives where environmental chemicals and any potential risks
associated with them are concerned.
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